<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EXUBERA- insulin human 
			 </strong><br><strong>EXUBERA- insulin human aerosol, powder </strong><br>Pfizer Inc.<br></p></div>
<h1>EXUBERA<span class="Sup">®</span><br>(insulin human [rDNA origin]) Inhalation Powder<br>EXUBERA<span class="Sup">®</span> Inhaler</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">EXUBERA<span class="Sup">®</span> consists of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> containing human insulin inhalation powder, which are administered using the EXUBERA<span class="Sup">®</span> Inhaler. EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> contain human insulin produced by recombinant DNA technology utilizing a non-pathogenic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Escherichia coli</span> (K12). Chemically, human insulin has the empirical formula C<span class="Sub">257</span>H<span class="Sub">383</span>N<span class="Sub">65</span>O<span class="Sub">77</span>S<span class="Sub">6</span> and a molecular weight of 5808. Human insulin has the following primary amino acid sequence:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-01.jpg"></p>
<p>EXUBERA (insulin human [rDNA origin]) Inhalation Powder is a white to off-white powder in a unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> (fill <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, see <a href="#T1">Table 1</a>). Each unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> of EXUBERA contains a  1 mg or 3 mg dose of insulin (see <a href="#T1">Table 1</a>) in a homogeneous powder formulation containing sodium citrate (dihydrate), mannitol, glycine, and sodium hydroxide. After an EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> is inserted into the inhaler, the patient pumps the handle of the inhaler and then presses a button, causing the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> to be pierced. The insulin inhalation powder is then dispersed into the chamber, allowing the patient to inhale the aerosolized powder.</p>
<p>Under standardized <span class="Italics">in vitro</span> test conditions, EXUBERA delivers a specific emitted dose of insulin from the mouthpiece of the inhaler (see <a href="#T1">Table 1</a>). A fraction of the total particle <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> is emitted as fine particles capable of reaching the deep lung. Up to 45% of the 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> contents, and up to 25% of the 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> contents, may be retained in the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</p>
<a name="T1"></a><table width="90%">
<caption><span>Table 1:	Dose Nomenclature and Information</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Fill <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span><br>(mg powder)</th>
<th class="Lrule" align="center">Nominal Dose<br>(mg insulin)</th>
<th class="Lrule" align="center">Emitted Dose<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br>(mg insulin)</th>
<th class="Lrule Rrule" align="center">Fine Particle Dose<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-2" class="Sup">†</a><br>(mg insulin)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Flow rate of 30 L/min for 2.5 seconds</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Emitted dose and fine particle dose information are not intended to predict actual pharmacodynamic response.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Flow rate of 28.3 L/min for 3 seconds</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">1.7</td>
<td class="Botrule Lrule" align="center">1.0</td>
<td class="Botrule Lrule" align="center">0.53</td>
<td class="Botrule Lrule Rrule" align="center">0.4</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">5.1</td>
<td class="Lrule" align="center">3.0</td>
<td class="Lrule" align="center">2.03</td>
<td class="Lrule Rrule" align="center">1.0</td>
</tr>
</tbody>
</table>
<p>The actual amount of insulin delivered to the lung will depend on individual patient factors, such as inspiratory flow profile. <span class="Italics">In vitro</span>, emitted aerosol metrics are unaffected at flow rates above 10 L/min.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-4.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The primary activity of insulin is regulation of glucose metabolism. Insulin lowers blood glucose concentrations by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-4.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">EXUBERA delivers insulin by oral inhalation. The insulin is absorbed as quickly as subcutaneously administered rapid-acting insulin analogs and more quickly than subcutaneously administered regular human insulin in healthy subjects and in patients with type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <a href="#F1">Figure 1</a>).<br><br></p>
<p class="Multimediacaption">Figure 1: Mean Changes in Free Insulin Serum Concentrations (µU/mL) in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Following Administration of Single Doses of Inhaled Insulin from EXUBERA (6 mg) and Subcutaneous Regular Human Insulin (18U)<br><a name="F1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-02.jpg"></p>
<p>In clinical studies in patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, after inhalation of EXUBERA, serum insulin reached peak concentration more quickly than after subcutaneous injection of regular human insulin, 49 minutes (range 30 to 90 minutes) compared to 105 minutes (range 60 to 240 minutes), respectively. </p>
<p>In clinical studies, the absorption of subcutaneous regular human insulin declined with increasing patient body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI). However, the absorption of insulin following inhalation of EXUBERA was independent of BMI.</p>
<p>In a study in healthy subjects, systemic insulin exposure (AUC and C<span class="Sub">max</span>) following administration of EXUBERA increased with dose over a range of 1 to 6 mg when administered as combinations of 1 and 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.</p>
<p>In a study where the dosage form of three 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> was compared with one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, C<span class="Sub">max</span> and AUC after administration of three 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> were approximately 30% and 40% greater, respectively, than that after administration of one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> (see <a href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2"></a><p></p>
<h3>Distribution and Elimination</h3>
<p class="First">Because recombinant human insulin is identical to endogenous insulin, the systemic distribution and elimination are expected to be the same. However, this has not been confirmed for EXUBERA.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-4.3"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">EXUBERA, like subcutaneously administered rapid-acting insulin analogs, has a more rapid onset of glucose-lowering activity than subcutaneously administered regular human insulin. In healthy volunteers, the duration of glucose-lowering activity for EXUBERA was comparable to subcutaneously administered regular human insulin and longer than subcutaneously administered rapid-acting insulin analogs (see <a href="#F2">Figure 2</a>).<br><br></p>
<p class="Multimediacaption">Figure 2. Mean Glucose Infusion Rate (GIR) Normalized to GIR<span class="Sub">max</span> for Each Subject Treatment Versus Time in Healthy Volunteers<br><a name="F2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-03.jpg"></p>
<p>*Determined as amount of glucose infused to maintain constant plasma glucose concentrations, normalized to maximum values (percent of maximum values); indicative of insulin activity.</p>
<p>When EXUBERA is inhaled, the onset of glucose-lowering activity in healthy volunteers occurs within 10–20 minutes. The maximum effect on glucose lowering is exerted approximately 2 hours after inhalation. The duration of glucose-lowering activity is approximately 6 hours.</p>
<p>In patients with type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA has a greater glucose-lowering effect within the first two hours after dosing when compared with subcutaneously administered regular human insulin.</p>
<p>The intra-subject variability of glucose-lowering activity of EXUBERA is generally comparable to that of subcutaneously administered regular human insulin in patients with type 1 and 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Special_Populations"></a><a name="section-4.4"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.1"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">In children (6–11 years) and adolescents (12–17 years) with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, time to peak insulin concentration for EXUBERA was achieved faster than for subcutaneous regular human insulin, which is consistent with observations in adult patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.2"></a><p></p>
<h3>Geriatric Patients</h3>
<p class="First">There are no apparent differences in the pharmacokinetic properties of EXUBERA when comparing patients over the age of 65 years and younger adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.3"></a><p></p>
<h3>Gender</h3>
<p class="First">In subjects with and without <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, no apparent differences in the pharmacokinetic properties of EXUBERA were observed between men and women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.4"></a><p></p>
<h3>Race</h3>
<p class="First">A study was performed in 25 healthy Caucasian and Japanese non-diabetic subjects to compare the pharmacokinetic and pharmacodynamic properties of EXUBERA, versus subcutaneous injection of regular human insulin. The pharmacokinetic and pharmacodynamic properties of EXUBERA were comparable between the two populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></h3>
<p class="First">The absorption of EXUBERA is independent of patient BMI. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of EXUBERA has not been studied. Careful glucose monitoring and dose adjustments of insulin may be necessary in patients with renal dysfunction (see <a href="#Renal_Impairment">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.7"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of EXUBERA has not been studied. Careful glucose monitoring and dose adjustments of insulin may be necessary in patients with hepatic dysfunction (see <a href="#Hepatic_Impairment">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.8"></a><p></p>
<h3>Pregnancy</h3>
<p class="First">The absorption of EXUBERA in pregnant patients with gestational and pre-gestational type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was consistent with that in non-pregnant patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (see <a href="#Pregnancy">PRECAUTIONS, Pregnancy</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Smoking"></a><a name="section-4.4.9"></a><p></p>
<h3>Smoking</h3>
<p class="First">In smokers, the systemic insulin exposure for EXUBERA is expected to be 2 to 5 fold higher than in non-smokers. EXUBERA is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting EXUBERA therapy. If a patient starts or resumes smoking, EXUBERA must be discontinued immediately due to the increased risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and an alternative treatment must be utilized (see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>).</p>
<p>In clinical studies of EXUBERA in 123 patients (69 of whom were smokers), smokers experienced a more rapid onset of glucose-lowering action, greater maximum effect, and a greater total glucose-lowering effect (particularly during the first 2–3 hours after dosing), compared to non-smokers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.10"></a><p></p>
<h3>Passive Cigarette Smoke</h3>
<p class="First">In contrast to the increase in insulin exposure following active smoking, when EXUBERA was administered to 30 healthy non-smoking volunteers following 2 hours of exposure to passive cigarette smoke in a controlled experimental setting, insulin AUC and Cmax were reduced by approximately 20% and 30%, respectively. The pharmacokinetics of EXUBERA have not been studied in <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> who are chronically exposed to passive cigarette smoke.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.11"></a><p></p>
<h3>Patients with Underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Diseases</span></h3>
<p class="First">The use of EXUBERA in patients with underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, is not recommended because the safety and efficacy of EXUBERA in this population have not been established (see <a href="#WARNINGS">WARNINGS</a>). The use of EXUBERA is contraindicated in patients with unstable or poorly controlled <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, because of wide variations in lung function that could affect the absorption of EXUBERA and increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>).</p>
<p>In a pharmacokinetic study in 24 non-diabetic subjects with mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, the absorption of insulin following administration of EXUBERA, in the absence of treatment with a bronchodilator, was approximately 20% lower than the absorption seen in subjects without <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. However, in a study in 24 non-diabetic subjects with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), the systemic exposure following administration of EXUBERA was approximately two-fold higher than that in normal subjects without <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> (see <a href="#Underlying_Lung_Disease">PRECAUTIONS, Underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></a>).</p>
<p>Administration of albuterol 30 minutes prior to administration of EXUBERA in non-diabetic subjects with both mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (n=36) and moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (n=31) resulted in a mean increase in insulin AUC and C<span class="Sub">max</span> of between 25 and 50% compared to when EXUBERA was administered alone (see <a href="#Drug_Interactions">PRECAUTIONS, Drug Interactions</a>). </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of EXUBERA has been studied in approximately 2500 adult patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The primary efficacy parameter for most studies was glycemic control, as measured by the reduction from baseline in hemoglobin A1c (HbA<span class="Sub">1c</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">A 24-week, randomized, open-label, active-control study (Study A) was conducted in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> to assess the safety and efficacy of EXUBERA administered pre-meal three times daily (TID) with a single nighttime injection of Humulin<span class="Sup">®</span> U Ultralente<span class="Sup">®</span> (human insulin extended zinc suspension) (n = 136). The comparator treatment was subcutaneous regular human insulin administered twice daily (BID) (pre-breakfast and pre-dinner) with BID injection of NPH human insulin (human insulin isophane suspension) (n = 132).  In this study, the mean age was 38.2 years (range: 20–64) and 52% of the subjects were male.</p>
<p>A second 24-week, randomized, open-label, active-control study (Study B) was conducted in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> to assess the safety and efficacy of EXUBERA (n = 103) compared to subcutaneous regular human insulin (n = 103) when administered TID prior to meals. In both treatment arms, NPH human insulin was administered BID (in the morning and at bedtime) as the basal insulin. In this study, the mean age was 38.4 years (range: 19–65) and 54% of the subjects were male.</p>
<p>In each study, the reduction in HbA<span class="Sub">1c</span> and the rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were comparable for the two treatment groups. EXUBERA-treated patients had a greater reduction in fasting plasma glucose than patients in the comparator group. The percentage of patients reaching an HbA<span class="Sub">1c</span> level of &lt;8% (per American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at the time of study conduct) and an HbA<span class="Sub">1c</span> level of &lt;7% was comparable between the two treatment groups. The results for Studies A and B are shown in Table 2.</p>
<table width="90%">
<caption><span>Table 2:	Results of Two 24-Week, Active-Control, Open-Label Trials in Patients With Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Studies A and B)</span></caption>
<col align="left" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left" rowspan="2"></th>
<th class="Botrule Lrule" align="center" colspan="2">Study A</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">Study B</th>
</tr>
<tr>
<th class="Botrule Lrule" align="center">EXUBERA (TID) + UL (QD)</th>
<th class="Botrule" align="center">SC R (BID) + NPH (BID)</th>
<th class="Botrule Lrule" align="center">EXUBERA (TID) + NPH (BID)</th>
<th class="Botrule Rrule" align="center">SC R (TID) + NPH (BID)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left">Sample Size</th>
<th class="Lrule" align="center">136</th>
<th align="center">132</th>
<th class="Lrule" align="center">103</th>
<th class="Rrule" align="center">103</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">UL = Humulin<span class="Sup">®</span> U Ultralente<span class="Sup">®</span>; SC R = subcutaneous regular human insulin</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>A negative treatment difference favors EXUBERA</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at the time of study conduct</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>1 mg inhaled insulin from Exubera is approximately equivalent to 3 IU of subcutaneously injected regular human insulin (See <a href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a>)</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">7.9</td>
<td align="center">8.0</td>
<td class="Lrule" align="center">7.8</td>
<td class="Rrule" align="center">7.8</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-0.2</td>
<td align="center">-0.4</td>
<td class="Lrule" align="center">-0.3</td>
<td class="Rrule" align="center">-0.2</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Lrule" align="center" colspan="2">0.14</td>
<td class="Lrule Rrule" align="center" colspan="2">-0.11</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-0.03, 0.32)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-0.30, 0.08)</td>
</tr>
<tr>
<td class="Lrule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">191</td>
<td align="center">198</td>
<td class="Lrule" align="center">178</td>
<td class="Rrule" align="center">191</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-32</td>
<td align="center">-6</td>
<td class="Lrule" align="center">-23</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R</td>
<td class="Lrule" align="center" colspan="2">-27</td>
<td class="Lrule Rrule" align="center" colspan="2">-35</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-47, -6)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-58, -13)</td>
</tr>
<tr>
<td class="Lrule" align="left">2-hr Post-Prandial Glucose Concentration (mg/dL)</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">283</td>
<td align="center">305</td>
<td class="Lrule" align="center">273</td>
<td class="Rrule" align="center">293</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-21</td>
<td align="center">14</td>
<td class="Lrule" align="center">-1</td>
<td class="Rrule" align="center">-3</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R</td>
<td class="Lrule" align="center" colspan="2">-35</td>
<td class="Lrule Rrule" align="center" colspan="2">2</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-61, -8)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-29, 32)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 8%<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td class="Botrule Lrule" align="center">64.0%</td>
<td class="Botrule Rrule" align="center">68.2%</td>
<td class="Botrule Lrule" align="center">74.8%</td>
<td class="Botrule Rrule" align="center">66.0%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 7%</td>
<td class="Botrule Lrule" align="center">16.9%</td>
<td class="Botrule Rrule" align="center">19.7%</td>
<td class="Botrule Lrule" align="center">28.2%</td>
<td class="Botrule Rrule" align="center">30.1%</td>
</tr>
<tr>
<td class="Lrule" align="left">Body Weight</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean (kg)</td>
<td class="Lrule" align="center">77.4</td>
<td align="center">76.4</td>
<td class="Lrule" align="center">76.0</td>
<td class="Rrule" align="center">76.9</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline (kg)</td>
<td class="Lrule" align="center">0.4</td>
<td align="center">1.1</td>
<td class="Lrule" align="center">0.4</td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R</td>
<td class="Lrule" align="center" colspan="2">-0.72</td>
<td class="Lrule Rrule" align="center" colspan="2">-0.24</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-1.48, 0.04)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-1.07, 0.59)</td>
</tr>
<tr>
<td class="Lrule" align="left">End of study daily insulin dose</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Short-acting insulin</td>
<td class="Lrule" align="center">13.4 mg<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td align="center">18.3 IU</td>
<td class="Lrule" align="center">10.9 mg<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">25.7 IU</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Long-acting insulin</td>
<td class="Lrule" align="center">26.4 IU</td>
<td align="center">37.1 IU</td>
<td class="Lrule" align="center">31.5 IU</td>
<td class="Rrule" align="center">31.9 IU</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<h3>Monotherapy in Patients Not Optimally Controlled With Diet and Exercise Treatment</h3>
<p class="First">A 12-week, randomized, open-label, active-control study (Study C) was conducted in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> not optimally controlled with diet and exercise, assessing the safety and efficacy of pre-meal TID EXUBERA (n = 75) compared to an insulin-sensitizing agent. In this study, the mean age was 53.7 years (range: 28–80), 55% of the subjects were male and the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index was 32.3 kg/m<span class="Sup">2</span>.</p>
<p>At 12 weeks, HbA<span class="Sub">1c</span> levels in patients treated with EXUBERA decreased 2.2% (SD = 1.0) from a baseline of 9.5% (SD = 1.1). The proportion of patients treated with EXUBERA reaching an end-of-study HbA<span class="Sub">1c</span> level of &lt;8% increased to 82.7%.  The proportion of patients treated with EXUBERA reaching an end-of-study HbA<span class="Sub">1c</span> level of &lt;7 % was 44.6%. Fasting plasma glucose levels in patients treated with EXUBERA decreased 60 mg/dl from a baseline of 208 mg/dl. Patients treated with EXUBERA experienced a mean increase in body weight of 2 kg.  The rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher in the Exubera group than the group receiving an insulin-sensitizing agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<h3>Monotherapy and Add-On Therapy in Patients Previously Treated With Oral Agent Therapy</h3>
<p class="First">A 12-week, randomized, open-label, active-control study (Study D) was conducted in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who were currently receiving treatment, but were poorly controlled, with two oral agents (OA). Baseline OAs included an insulin secretagogue, and either metformin or a thiazolidinedione. Patients were randomized to one of three arms: continuing OA therapy alone (n = 96), switching to pre-meal TID EXUBERA monotherapy (n = 102) or adding pre-meal TID EXUBERA to continued OA therapy (n = 100). In this study, the mean age was 57.4 years (range: 33–80), 66% of the subjects were male and the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index was 30 kg/m<span class="Sup">2</span>.</p>
<p>EXUBERA monotherapy and EXUBERA in combination with OA therapy were superior to OA therapy alone in reducing HbA<span class="Sub">1c</span> levels from baseline. The rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> for the two EXUBERA treatment groups were slightly higher than in the OA therapy alone group. Compared to OA therapy alone, the percentage of patients reaching an HbA<span class="Sub">1c</span> level of &lt;8% (per American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at time of study conduct) and an HbA<span class="Sub">1c</span> level of &lt;7% was greater for patients treated with EXUBERA monotherapy and EXUBERA in combination with OA therapy. Patients in both EXUBERA treatment groups had greater reductions in fasting plasma glucose than patients treated with OA therapy alone. The results for Study D are shown in Table 3.</p>
<table width="100%">
<caption><span>Table 3:	Results of a 12-Week, Active-Control, Open-Label Trial in Patients With Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Not Optimally Controlled With Dual Oral Agent Therapy (Study D)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="7%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="First">
<th class="Lrule" align="left">Study D</th>
<th class="Lrule" align="center">EXUBERA monotherapy</th>
<th align="center"></th>
<th align="center">OAs<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</th>
<th align="center"></th>
<th class="Rrule" align="center">EXUBERA + OAs</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left">Sample Size</th>
<th class="Lrule Toprule" align="center">102</th>
<th class="Toprule" align="center"></th>
<th class="Toprule" align="center">96</th>
<th class="Toprule" align="center"></th>
<th class="Rrule Toprule" align="center">100</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>OAs = treatment with two oral agents (an insulin secretagogue in addition to metformin or a thiazolidinedione)</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>A negative treatment difference favors EXUBERA </dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Comparison of EXUBERA monotherapy to combination oral agent therapy alone</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>
<span class="Italics">p</span> &lt; 0.0001</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">¶</a></dt>
<dd>Comparison of EXUBERA plus oral agents to combination oral agent therapy alone</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">#</a></dt>
<dd>American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at the time of study conduct</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Lrule" align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">9.3</td>
<td align="center"></td>
<td align="center">9.3</td>
<td align="center"></td>
<td class="Rrule" align="center">9.2</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-1.4</td>
<td align="center"></td>
<td align="center">-0.2</td>
<td align="center"></td>
<td class="Rrule" align="center">-1.9</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA group minus OAs<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Lrule" align="right" colspan="2">-1.18<a href="#footnote-8" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>  </td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">  -1.67<a href="#footnote-8" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">¶</a><span class="Sup">,</span><a href="#footnote-10" class="Sup">§</a>
</td>
</tr>
<tr>
<td class="Lrule" align="left">    95% CI for treatment difference</td>
<td class="Lrule" align="right" colspan="2">(-1.41, -0.95)</td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">(-1.90, -1.44)</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Lrule Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">203</td>
<td align="center"></td>
<td align="center">203</td>
<td align="center"></td>
<td class="Rrule" align="center">195</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-23</td>
<td align="center"></td>
<td align="center">1</td>
<td align="center"></td>
<td class="Rrule" align="center">-53</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA group minus OAs</td>
<td class="Lrule" align="right" colspan="2">-24<a href="#footnote-9" class="Sup">‡</a>    </td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">    -53<a href="#footnote-11" class="Sup">¶</a>
</td>
</tr>
<tr>
<td class="Lrule" align="left">    95% CI for treatment difference</td>
<td class="Lrule" align="right" colspan="2">(-36, -11)</td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">(-66, -41)</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 8%<a name="footnote-reference-12" href="#footnote-12" class="Sup">#</a>
</td>
<td class="Lrule Toprule" align="center">55.9%</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">18.8%</td>
<td class="Toprule" align="center"></td>
<td class="Rrule Toprule" align="center">86.0%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 7%</td>
<td class="Lrule Toprule" align="center">16.7%</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">1.0%</td>
<td class="Toprule" align="center"></td>
<td class="Rrule Toprule" align="center">32.0%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Body Weight</td>
<td class="Lrule Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean (kg)</td>
<td class="Lrule" align="center">89.5</td>
<td align="center"></td>
<td align="center">88.0</td>
<td align="center"></td>
<td class="Rrule" align="center">88.6</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline (kg)</td>
<td class="Lrule" align="center">2.8</td>
<td align="center"></td>
<td align="center">0.0</td>
<td align="center"></td>
<td class="Rrule" align="center">2.7</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA group minus OAs</td>
<td class="Lrule" align="right" colspan="2">2.80<a href="#footnote-9" class="Sup">‡</a>    </td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">    2.75<a href="#footnote-11" class="Sup">¶</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">    95% CI for treatment difference</td>
<td class="Lrule" align="right" colspan="2">(1.94, 3.65)</td>
<td align="center"></td>
<td class="Rrule" align="left" colspan="2">(1.89, 3.61)</td>
</tr>
</tbody>
</table>
<p>A 24-week, randomized, open-label, active-control study (Study E) was conducted in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, currently receiving sulfonylurea therapy.  This study was designed to assess the safety and efficacy of the addition of pre-meal EXUBERA to continued sulfonylurea therapy (n = 214) compared to the addition of pre-meal metformin to continued sulfonylurea therapy (n = 196). Subjects were stratified according to their HbA<span class="Sub">1c</span> at Week -1. Two strata were defined: a low HbA1c stratum (HbA<span class="Sub">1c</span> ≥8% to ≤9.5%) and a high HbA<span class="Sub">1c</span> stratum (HbA<span class="Sub">1c</span> &gt;9.5 to ≤12%).</p>
<p>EXUBERA in combination with sulfonylurea was superior to metformin and sulfonylurea in reducing HbA<span class="Sub">1c</span> values from baseline in the high stratum group. EXUBERA in combination with sulfonylurea was comparable to metformin in combination with sulfonylurea in reducing HbA<span class="Sub">1c</span> values from baseline in the low stratum group. The rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher after the addition of EXUBERA to sulfonylurea than after the addition of metformin to sulfonylurea. The percentage of patients reaching target HbA<span class="Sub">1c</span> values of 8% and 7% was comparable between treatment groups in both strata, as was reduction in fasting plasma glucose (see <a href="#T4">Table 4</a>).</p>
<p>Another 24-week, randomized, open-label, active-control study (Study F) was conducted in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, currently receiving metformin therapy.  This study was designed to assess the safety and efficacy of the addition of pre-meal EXUBERA to continued metformin therapy (n = 234) compared to the addition of pre-meal glibenclamide to continued metformin therapy (n = 222). Subjects in this study were also stratified to one of two strata as defined in Study E.</p>
<p>EXUBERA in combination with metformin was superior to glibenclamide and metformin in reducing HbA<span class="Sub">1c</span> values from baseline and achieving target HbA<span class="Sub">1c</span> values in the high stratum group. EXUBERA in combination with metformin was comparable to glibenclamide in combination with metformin in reducing HbA<span class="Sub">1c</span> values from baseline and achieving target HbA<span class="Sub">1c</span> values in the low stratum group. The rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was slightly higher after the addition of EXUBERA to metformin than after the addition of glibenclamide to metformin. Reduction in fasting plasma glucose was comparable between treatment groups (see <a href="#T4">Table 4</a>).</p>
<a name="T4"></a><table width="100%">
<caption><span>Table 4:	Results of Two 24-Week, Active-Control, Open-Label Trials in Patients With Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Previously On Oral Agent Therapy (Studies E and F)</span></caption>
<col align="left" valign="top" width="36%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="4">Study E</th>
<th class="Botrule Lrule Rrule" align="center" colspan="4">Study F</th>
</tr>
<tr>
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Exubera + SU<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</th>
<th align="center">Met<a href="#footnote-13" class="Sup">*</a>+ SU<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Lrule" align="center">Exubera + SU<a href="#footnote-13" class="Sup">*</a>
</th>
<th align="center">Met<a href="#footnote-13" class="Sup">*</a>+ SU<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Lrule" align="center">Exubera + Met<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Lrule" align="center">Gli<a href="#footnote-13" class="Sup">*</a> + Met<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Lrule" align="center">Exubera + Met<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center">Gli<a href="#footnote-13" class="Sup">*</a> + Met<a href="#footnote-13" class="Sup">*</a>
</th>
</tr>
<tr>
<th class="Lrule Toprule" align="left"></th>
<th class="Lrule Toprule" align="center" colspan="2">High stratum<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a>
</th>
<th class="Lrule Toprule" align="center" colspan="2">Low stratum<a href="#footnote-14" class="Sup">†</a>
</th>
<th class="Lrule Toprule" align="center" colspan="2">High stratum<a href="#footnote-14" class="Sup">†</a>
</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Low stratum<a href="#footnote-14" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left">Sample Size</th>
<th class="Lrule Toprule" align="center">113</th>
<th class="Lrule Toprule" align="center">103</th>
<th class="Lrule Toprule" align="center">101</th>
<th class="Lrule Toprule" align="center">93</th>
<th class="Lrule Toprule" align="center">109</th>
<th class="Lrule Toprule" align="center">103</th>
<th class="Lrule Toprule" align="center">125</th>
<th class="Lrule Rrule Toprule" align="center">119</th>
</tr>
</thead>
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>SU = sulfonylurea, Met = metformin, Gli = glibenclamide</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Low stratum = entry HbA1c ≥8.0% to ≤9.5%; high stratum = entry HbA1c &gt;9.5% to ≤12% </dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>A negative treatment difference favors EXUBERA</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">§</a></dt>
<dd>
<span class="Italics">p</span> = 0.002</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">¶</a></dt>
<dd>
<span class="Italics">p</span> = 0.004</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">#</a></dt>
<dd>American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at the time of study conduct</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">10.5</td>
<td align="center">10.6</td>
<td class="Lrule" align="center">8.8</td>
<td align="center">8.8</td>
<td class="Lrule" align="center">10.4</td>
<td align="center">10.6</td>
<td class="Lrule" align="center">8.6</td>
<td class="Rrule" align="center">8.7</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-2.2</td>
<td align="center">-1.8</td>
<td class="Lrule" align="center">-1.9</td>
<td align="center">-1.9</td>
<td class="Lrule" align="center">-2.2</td>
<td align="center">-1.9</td>
<td class="Lrule" align="center">-1.8</td>
<td class="Rrule" align="center">-1.9</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus OA<a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a>
</td>
<td class="Lrule" align="center" colspan="2">-0.38<a href="#footnote-15" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">§</a>
</td>
<td class="Lrule" align="center" colspan="2">-0.07</td>
<td class="Lrule" align="center" colspan="2">-0.37<a href="#footnote-15" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">¶</a>
</td>
<td class="Lrule Rrule" align="center" colspan="2">0.04</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-0.63, -0.14)</td>
<td class="Botrule Lrule" align="center" colspan="2">(-0.33, 0.19)</td>
<td class="Botrule Lrule" align="center" colspan="2">(-0.62, -0.12)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-0.19, 0.27)</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">241</td>
<td align="center">237</td>
<td class="Lrule" align="center">197</td>
<td align="center">198</td>
<td class="Lrule" align="center">223</td>
<td align="center">243</td>
<td class="Lrule" align="center">187</td>
<td class="Rrule" align="center">196</td>
</tr>
<tr>
<td class="Lrule" align="left">  Mean change from baseline</td>
<td class="Lrule" align="center">-46</td>
<td align="center">-47</td>
<td class="Lrule" align="center">-48</td>
<td align="center">-52</td>
<td class="Lrule" align="center">-42</td>
<td align="center">-40</td>
<td class="Lrule" align="center">-46</td>
<td class="Rrule" align="center">-49</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus OA</td>
<td class="Lrule" align="center" colspan="2">1</td>
<td class="Lrule" align="center" colspan="2">4</td>
<td class="Lrule" align="center" colspan="2">-2</td>
<td class="Lrule Rrule" align="center" colspan="2">4</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(-11, 12)</td>
<td class="Botrule Lrule" align="center" colspan="2">(-8, 16)</td>
<td class="Botrule Lrule" align="center" colspan="2">(-14, 10)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-7, 15)</td>
</tr>
<tr>
<td class="Lrule" align="left">Subjects with end-of-study HbA<span class="Sub">1c</span> &lt; 8%<a name="footnote-reference-18" href="#footnote-18" class="Sup">#</a>
</td>
<td class="Lrule" align="center">48.7%</td>
<td align="center">44.7%</td>
<td class="Lrule" align="center">81.2%</td>
<td align="center">73.1%</td>
<td class="Lrule" align="center">72.5%</td>
<td align="center">56.3%</td>
<td class="Lrule" align="center">80.8%</td>
<td class="Rrule" align="center">86.6%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Subjects with end-of-study HbA<span class="Sub">1c</span> &lt; 7%</td>
<td class="Lrule Toprule" align="center">20.4%</td>
<td class="Toprule" align="center">14.6%</td>
<td class="Lrule Toprule" align="center">30.7%</td>
<td class="Toprule" align="center">32.3%</td>
<td class="Lrule Toprule" align="center">33.9%</td>
<td class="Toprule" align="center">17.5%</td>
<td class="Lrule Toprule" align="center">40.0%</td>
<td class="Rrule Toprule" align="center">42.9%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Body Weight</td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Toprule" align="center" colspan="2"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean (kg)</td>
<td class="Lrule" align="center">80.8</td>
<td align="center">79.5</td>
<td class="Lrule" align="center">79.9</td>
<td align="center">81.9</td>
<td class="Lrule" align="center">88.3</td>
<td align="center">87.8</td>
<td class="Lrule" align="center">90.3</td>
<td class="Rrule" align="center">88.2</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline (kg)</td>
<td class="Lrule" align="center">3.6</td>
<td align="center">-0.0</td>
<td class="Lrule" align="center">2.4</td>
<td align="center">-0.3</td>
<td class="Lrule" align="center">2.8</td>
<td align="center">2.5</td>
<td class="Lrule" align="center">2.0</td>
<td class="Rrule" align="center">1.6</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus OA</td>
<td class="Lrule" align="center" colspan="2">3.60</td>
<td class="Lrule" align="center" colspan="2">2.67</td>
<td class="Lrule" align="center" colspan="2">0.26</td>
<td class="Lrule Rrule" align="center" colspan="2">0.38</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule" align="center" colspan="2">(2.81, 4.39)</td>
<td class="Botrule Lrule" align="center" colspan="2">(1.84, 3.51)</td>
<td class="Botrule Lrule" align="center" colspan="2">(-0.70, 1.21)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-0.52, 1.27)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.3"></a><p></p>
<h3>Use in Patients Previously Treated With Subcutaneous Insulin</h3>
<p class="First">A 24-week, randomized, open-label, active-control study (Study G) was conducted in insulin-treated patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> to assess the safety and efficacy of EXUBERA administered pre-meal TID with a single nighttime injection of Humulin<span class="Sup">®</span> U Ultralente<span class="Sup">®</span> (n = 146) compared to subcutaneous regular human insulin administered BID (pre-breakfast and pre-dinner) with BID injection of NPH human insulin (n = 149). In this study, the mean age was 57.5 years (range: 23–80), 66% of the subjects were male and the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index was 30.3 kg/m<span class="Sup">2</span>.</p>
<p>The reductions from baseline in HbA<span class="Sub">1c</span>, percent of patients reaching an HbA<span class="Sub">1c</span> level of &lt;8% (per American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at time of study conduct) and an HbA<span class="Sub">1c</span> level of &lt;7%, as well as the rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, were similar between treatment groups. EXUBERA-treated patients had a greater reduction in fasting plasma glucose than patients in the comparator group. The results for Study G are shown in Table 5.</p>
<table width="80%">
<caption><span>Table 5:	Results of a 24-Week, Active-Control, Open-Label Trial in Patients With Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Previously Treated With Subcutaneous Insulin (Study G)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="left">Study G</th>
<th class="Lrule" align="center">EXUBERA (TID) + UL (QD)</th>
<th class="Lrule Rrule" align="center">SC R (BID) + NPH (BID)</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left">Sample Size</th>
<th class="Lrule Toprule" align="center">146</th>
<th class="Lrule Rrule Toprule" align="center">149</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">UL = Humulin<span class="Sup">®</span> U Ultralente<span class="Sup">®</span>; SC R = subcutaneous regular human insulin</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-19" href="#footnote-reference-19">*</a></dt>
<dd>A negative treatment difference favors EXUBERA</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">†</a></dt>
<dd>American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association treatment Action Level at the time of study conduct</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">‡</a></dt>
<dd>1 mg inhaled insulin from Exubera is approximately equivalent to 3 IU of subcutaneously injected regular human insulin. See <a href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a>
</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">HbA<span class="Sub">1c</span> (%)</td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">8.1</td>
<td class="Rrule" align="center">8.2</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-0.7</td>
<td class="Rrule" align="center">-0.6</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R<a name="footnote-reference-19" href="#footnote-19" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center" colspan="2">-0.07</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-0.31, 0.17)</td>
</tr>
<tr>
<td class="Lrule" align="left">Fasting Plasma Glucose (mg/dL)</td>
<td class="Lrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean</td>
<td class="Lrule" align="center">152</td>
<td class="Rrule" align="center">159</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline</td>
<td class="Lrule" align="center">-22</td>
<td class="Rrule" align="center">-6</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R</td>
<td class="Lrule Rrule" align="center" colspan="2">-16.36</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-27.09, -5.36)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 8%<a name="footnote-reference-20" href="#footnote-20" class="Sup">†</a>
</td>
<td class="Botrule Lrule" align="center">76.0%</td>
<td class="Botrule Rrule" align="center">69.1%</td>
</tr>
<tr>
<td class="Lrule" align="left">Patients with end-of-study HbA<span class="Sub">1c</span> &lt; 7%</td>
<td class="Lrule" align="center">45.2%</td>
<td class="Rrule" align="center">32.2%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Body Weight</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Baseline mean (kg)</td>
<td class="Lrule" align="center">90.6</td>
<td class="Rrule" align="center">89.0</td>
</tr>
<tr>
<td class="Lrule" align="left">  Adj. mean change from baseline (kg)</td>
<td class="Lrule" align="center">0.1</td>
<td class="Rrule" align="center">1.3</td>
</tr>
<tr>
<td class="Lrule" align="left">    EXUBERA minus SC R</td>
<td class="Lrule Rrule" align="center" colspan="2">-1.28</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    95% CI for treatment difference</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">(-1.96, -0.60)</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">End of study daily insulin dose</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Short-acting insulin</td>
<td class="Lrule" align="center">16.6 mg<a name="footnote-reference-21" href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">25.5 IU</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Long-acting insulin</td>
<td class="Lrule" align="center">37.9 IU</td>
<td class="Rrule" align="center">52.3 IU</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">EXUBERA is indicated for the treatment of adult patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus for the control of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">EXUBERA is contraindicated in patients hypersensitive to EXUBERA or one of its excipients.</p>
<p>EXUBERA is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting EXUBERA therapy. If a patient starts or resumes smoking, EXUBERA must be discontinued immediately due to the increased risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and an alternative treatment must be utilized (see <a href="#Smoking">CLINICAL PHARMACOLOGY, Special Populations, Smoking</a>). The safety and efficacy of EXUBERA in patients who smoke have not been established.</p>
<p>EXUBERA is contraindicated in patients with unstable or poorly controlled <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, because of wide variations in lung function that could affect the absorption of EXUBERA and increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">EXUBERA differs from regular human insulin by its rapid onset of action. When used as mealtime insulin, the dose of EXUBERA should be given within 10 minutes before a meal.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most commonly reported adverse event of insulin therapy, including EXUBERA. The timing of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may differ among various insulin formulations.</span></p>
<p><span class="Bold">Patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> also require a longer-acting insulin to maintain adequate glucose control.</span></p>
<p><span class="Bold">Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH, analogs), or species (animal, human) may result in the need for a change in dosage. Concomitant oral antidiabetic treatment may need to be adjusted.</span></p>
<p>Glucose monitoring is recommended for all patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p><span class="Bold">Because of the effect of EXUBERA on pulmonary function, all patients should have pulmonary function assessed prior to initiating therapy with EXUBERA (see <a href="#Pulmonary_Function">PRECAUTIONS: Pulmonary Function</a>).</span></p>
<p><span class="Bold">The use of EXUBERA in patients with underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, is not recommended because the safety and efficacy of EXUBERA in this population have not been established (see <a href="#Underlying_Lung_Disease">PRECAUTIONS: Underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></a>).</span></p>
<p>In clinical trials of Exubera, there have been 6 newly diagnosed cases of primary lung malignancies among Exubera-treated patients, and 1 newly diagnosed case among comparator-treated patients.  There has also been 1 postmarketing report of a primary lung malignancy in an Exubera-treated patient.  In controlled clinical trials of Exubera, the incidence of new primary lung cancer per 100 patient-years of study drug exposure was 0.13 (5 cases over 3900 patient-years) for Exubera-treated patients and 0.02 (1 case over 4100 patient-years) for comparator-treated patients. There were too few cases to determine whether the emergence of these events is related to Exubera. All patients who were diagnosed with lung cancer had a prior history of cigarette smoking. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">As with all insulin preparations, the time course of EXUBERA action may vary in different individuals or at different times in the same individual. Adjustment of dosage of any insulin may be necessary if patients change their physical activity or their usual meal plan. Insulin requirements may be altered during intercurrent conditions such as illness, <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>, or stress.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">As with all insulin preparations, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> may be associated with the administration of EXUBERA. Rapid changes in serum glucose concentrations may induce symptoms similar to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in persons with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, regardless of the glucose value. Early warning symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be different or less pronounced under certain conditions, such as long duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, diabetic nerve disease, use of medications such as beta-blockers, or intensified <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> control (see <a href="#Drug_Interactions">PRECAUTIONS, Drug Interactions</a>). Such situations may result in severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (and, possibly, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>) prior to patients' awareness of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Renal_Impairment"></a><a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Studies have not been performed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. As with other insulin preparations, the dose requirements for EXUBERA may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Hepatic_Impairment"></a><a name="section-9.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Studies have not been performed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. As with other insulin preparations, the dose requirements for EXUBERA may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5.1"></a><p></p>
<h3>Systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h3>
<p class="First">In clinical studies, the overall incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in patients treated with EXUBERA was similar to that in patients using subcutaneous regimens with regular human insulin.</p>
<p>As with other insulin preparations, rare, but potentially serious, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to insulin may occur, which may cause <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) over the whole body, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, reduction in blood pressure, rapid pulse, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. Severe cases of generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, may be life threatening.  If such reactions occur from EXUBERA, EXUBERA should be stopped and alternative therapies considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5.2"></a><p></p>
<h3>Antibody Production</h3>
<p class="First">Insulin antibodies may develop during treatment with all insulin preparations including EXUBERA. In clinical studies of EXUBERA where the comparator was subcutaneous insulin, increases in insulin antibody levels (as reflected by assays of insulin binding activity) were significantly greater for patients who received EXUBERA than for patients who received subcutaneous insulin only. No clinical consequences of these antibodies were identified over the time period of clinical studies of EXUBERA; however, the long-term clinical significance of this increase in antibody formation is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>Respiratory</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Pulmonary_Function"></a><a name="section-9.6.1"></a><p></p>
<h3>Pulmonary Function</h3>
<p class="First">In clinical trials up to two years duration, patients treated with EXUBERA demonstrated a greater decline in pulmonary function, specifically the forced expiratory volume in one second (FEV<span class="Sub">1</span>) and the <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> diffusing capacity (DL<span class="Sub">CO</span>), than comparator-treated patients.  The mean treatment group difference in pulmonary function favoring the comparator group, was noted within the first several weeks of treatment with EXUBERA, and did not change over the two year treatment period (See <a href="#A_Pulmonary_Function">ADVERSE REACTIONS: Pulmonary Function</a>). </p>
<p>During the controlled clinical trials, individual patients experienced notable declines in pulmonary function in both treatment groups.  A decline from baseline FEV<span class="Sub">1</span> of ≥ 20% at last observation occurred in 1.5% of EXUBERA-treated and 1.3% of comparator-treated patients.  A decline from baseline DL<span class="Sub">CO</span> of ≥ 20% at last observation occurred in 5.1% of EXUBERA-treated and 3.6% of comparator treated patients.  </p>
<p>Because of the effect of EXUBERA on pulmonary function, all patients should have spirometry (FEV<span class="Sub">1</span>) assessed prior to initiating therapy with EXUBERA.  Assessment of DL<span class="Sub">CO</span> should be considered.  The efficacy and safety of EXUBERA in patients with baseline FEV<span class="Sub">1</span> or DL<span class="Sub">CO</span> &lt; 70% predicted have not been established and the use of EXUBERA in this population is not recommended.</p>
<p>Assessment of pulmonary function (e.g., spirometry) is recommended after the first 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms.  In patients who have a decline of ≥ 20% in FEV<span class="Sub">1</span> from baseline, pulmonary function tests should be repeated.  If the ≥ 20% decline from baseline FEV<span class="Sub">1</span> is confirmed, EXUBERA should be discontinued.  The presence of pulmonary symptoms and lesser declines in pulmonary function may require more frequent monitoring of pulmonary function and consideration of discontinuation of EXUBERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Underlying_Lung_Disease"></a><a name="section-9.6.2"></a><p></p>
<h3>Underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disease</span></h3>
<p class="First">The use of EXUBERA in patients with underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, is not recommended because the efficacy and safety of EXUBERA in this population have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> has been rarely reported in patients taking EXUBERA. Patients experiencing such a reaction should discontinue EXUBERA and seek medical evaluation immediately. Re-administration of EXUBERA requires a careful risk evaluation, and should only be done under close medical monitoring with appropriate clinical facilities available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6.4"></a><p></p>
<h3>Intercurrent Respiratory Illness</h3>
<p class="First">EXUBERA has been administered to patients with intercurrent respiratory illness (e.g. <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>) during clinical studies. In patients experiencing these conditions, 3–4% temporarily discontinued EXUBERA therapy. There was no increased risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or worsened glycemic control observed in EXUBERA-treated patients compared to patients treated with subcutaneous insulin. During intercurrent respiratory illness, close monitoring of blood glucose concentrations, and dose adjustment, may be required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-9.7"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed on self-management procedures including glucose monitoring; proper EXUBERA inhalation technique; and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> management. Patients must be instructed on handling of special situations such as intercurrent conditions (illness, stress, or <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, or skipped meals. Refer patients to the <a href="#medication">EXUBERA Patient Medication Guide </a>for additional information.</p>
<p>Patients should be informed that in clinical studies, treatment with EXUBERA was associated with small, non-progressive mean declines in pulmonary function relative to comparator treatments. Because of the effect of EXUBERA on pulmonary function, pulmonary function tests are recommended prior to initiating treatment with EXUBERA.  Following initiation of therapy, periodic pulmonary function tests are recommended (see <a href="#Pulmonary_Function">PRECAUTIONS, Respiratory, Pulmonary Function</a>).</p>
<p>Patients should inform their physician if they have a history of <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, because the use of EXUBERA is not recommended in patients with underlying <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), and is contraindicated in patients with poorly controlled <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>.</p>
<p>Women with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should be advised to inform their doctor if they are pregnant or are contemplating pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_Interactions"></a><a name="section-9.8"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.</p>
<p>The following are examples of substances that may reduce the blood glucose-lowering effect of insulin that may result in <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>: corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotic medications (e.g., olanzapine and clozapine).</p>
<p>The following are examples of substances that may increase the blood glucose-lowering effect of insulin and susceptibility to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, and sulfonamide antibiotics.</p>
<p>Beta-blockers, clonidine, lithium salts, and alcohol may either increase or reduce the blood glucose-lowering effect of insulin. Pentamidine may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, which may sometimes be followed by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p>In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent. </p>
<p>Bronchodilators and other inhaled products may alter the absorption of inhaled human insulin (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY, Special Populations</a>). Consistent timing of dosing of bronchodilators relative to EXUBERA administration, close monitoring of blood glucose concentrations and dose titration as appropriate are recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year carcinogenicity studies in animals have not been performed. Insulin was not mutagenic in the Ames bacterial reverse mutation test in the presence and absence of metabolic activation. </p>
<p>In Sprague-Dawley rats, a 6-month repeat-dose toxicity study was conducted with insulin inhalation powder at doses up to 5.8 mg/kg/day (compared to the clinical starting dose of 0.15 mg/kg/day, the rat high dose was 39 times or 8.3 times the clinical dose, based on either a mg/kg or a mg/m<span class="Sup">2</span> body surface area comparison).  In Cynomolgus monkeys, a 6-month repeat-dose toxicity study was conducted with inhaled insulin at doses up to 0.64 mg/kg/day.  Compared to the clinical starting dose of 0.15 mg/kg/day, the monkey high dose was 4.3 times or 1.4 times the clinical dose, based on either a mg/kg or a mg/m<span class="Sup">2</span> body surface area comparison. These were maximum tolerated doses based on <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>Compared to control animals, there were no treatment-related adverse effects in either species on pulmonary function, gross or microscopic morphology of the respiratory tract or bronchial lymph nodes. Similarly, there was no effect on cell proliferation indices in alveolar or bronchiolar area of the lung in either species.</p>
<p>Because recombinant human insulin is identical to the endogenous hormone, reproductive/fertility studies were not performed in animals.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-9.10"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-9.10.1"></a><p></p>
<h3>Teratogenic Effects </h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.10.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with EXUBERA. It is also not known whether EXUBERA can cause fetal harm when administered to a pregnant woman or whether EXUBERA can affect reproductive capacity. EXUBERA should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-9.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Many drugs, including human insulin, are excreted in human milk. For this reason, caution should be exercised when EXUBERA is administered to a nursing woman. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who are lactating may require adjustments in EXUBERA dose, meal plan, or both.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-9.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Long-term safety and effectiveness of EXUBERA in pediatric patients have not been established (see <a href="#Special_Populations">CLINICAL PHARMACOLOGY, Special Populations</a>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-9.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In controlled Phase 2/3 clinical studies (n=1975), EXUBERA was administered to 266 patients ≥65 years of age and 30 patients ≥75 years of age. The majority of these patients had type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The change in HbA<span class="Sub">1C</span> and rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> did not differ by age. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The safety of EXUBERA alone, or in combination with subcutaneous insulin or oral agents, has been evaluated in approximately 2500 adult patients with type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who were exposed to EXUBERA.  Approximately 2000 patients were exposed to EXUBERA for greater than 6 months and more than 800 patients were exposed for more than 2 years.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Non-Respiratory Adverse Events</h2>
<p class="First">Non-respiratory adverse events reported in ≥1% of 1977 EXUBERA-treated patients in controlled Phase 2/3 clinical studies, regardless of causality, include (but are not limited to) the following:</p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (see <a href="#WARNINGS">WARNINGS</a> and <a href="#PRECAUTIONS">PRECAUTIONS</a>)<br><span class="Bold">Body as a whole: </span><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span><br><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span><br><span class="Bold">Special senses: </span><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (type 1 pediatric diabetics)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h3>
<p class="First">The rates and incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were comparable between EXUBERA and subcutaneous regular human insulin in patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.  In type 2 patients who were not adequately controlled with single oral agent therapy, the addition of EXUBERA was associated with a higher rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> than was the addition of a second oral agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></h3>
<p class="First">A range of different chest symptoms were reported as adverse reactions and were grouped under the non-specific term <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. These events occurred in 4.7% of EXUBERA-treated patients and 3.2% of patients in comparator groups. The majority (&gt;90%) of these events were reported as mild or moderate. Two patients in the EXUBERA and one in the comparator group discontinued treatment due to <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. The incidence of all-causality adverse events related to <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, such as <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was comparable in the EXUBERA (0.7% <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>; 0.7% <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) and comparator (1.3% <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>; 0.7% <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) treatment groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> was reported in 2.4% of EXUBERA-treated patients and 0.8% of patients in comparator groups. Nearly all (&gt;98%) of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> reported was mild or moderate. No patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.4"></a><p></p>
<h3>Ear Events in Pediatric Diabetics</h3>
<p class="First">Pediatric type 1 diabetics in EXUBERA groups experienced adverse events related to the ear more frequently than did pediatric type 1 diabetics in treatment groups receiving only subcutaneous insulin.  These events included <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (EXUBERA 6.5%; SC 3.4%), <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span> (EXUBERA 3.9%; SC 1.4%), and <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorder</span> (EXUBERA 1.3%; SC 0%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Respiratory Adverse Events</h2>
<p class="First">Table 6 shows the incidence of respiratory adverse events for each treatment group that were reported in ≥1% of any treatment group in controlled Phase 2 and 3 clinical studies, regardless of causality.</p>
<table width="90%">
<caption><span>Table 6:	Respiratory Adverse Events Reported in ≥1% of Any Treatment Group in Controlled Phase 2 and 3 Clinical Studies, Regardless of Causality</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="14.4%">
<col align="center" valign="top" width="14.4%">
<col align="center" valign="top" width="14.4%">
<col align="center" valign="top" width="14.4%">
<col align="center" valign="top" width="14.4%">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="5">Percent of Patients Reporting Event</th>
</tr>
<tr>
<th class="Lrule" align="left" rowspan="2" valign="middle">Adverse Event</th>
<th class="Botrule Lrule" align="center" colspan="2">Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">EXUBERA<br>N = 698</th>
<th class="Lrule" align="center">SC<br>N = 705</th>
<th class="Lrule" align="center">EXUBERA<br>N = 1279</th>
<th class="Lrule" align="center">SC<br>N = 488</th>
<th class="Lrule Rrule" align="center">OAs<br>N = 644</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="6">SC = subcutaneous insulin comparator; OA = oral agent comparators</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infection</span></td>
<td class="Lrule" align="center">43.3</td>
<td class="Lrule" align="center">42.0</td>
<td class="Lrule" align="center">29.2</td>
<td class="Lrule" align="center">38.1</td>
<td class="Lrule Rrule" align="center">19.7</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></td>
<td class="Lrule Toprule" align="center">29.5</td>
<td class="Lrule Toprule" align="center">8.8</td>
<td class="Lrule Toprule" align="center">21.9</td>
<td class="Lrule Toprule" align="center">10.2</td>
<td class="Lrule Rrule Toprule" align="center">3.7</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Lrule Toprule" align="center">18.2</td>
<td class="Lrule Toprule" align="center">16.6</td>
<td class="Lrule Toprule" align="center">9.5</td>
<td class="Lrule Toprule" align="center">9.6</td>
<td class="Lrule Rrule Toprule" align="center">5.9</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Lrule Toprule" align="center">14.5</td>
<td class="Lrule Toprule" align="center">10.9</td>
<td class="Lrule Toprule" align="center">8.8</td>
<td class="Lrule Toprule" align="center">10.5</td>
<td class="Lrule Rrule Toprule" align="center">3.0</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule Toprule" align="center">10.3</td>
<td class="Lrule Toprule" align="center">7.4</td>
<td class="Lrule Toprule" align="center">5.4</td>
<td class="Lrule Toprule" align="center">10.0</td>
<td class="Lrule Rrule Toprule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorder</span></td>
<td class="Lrule Toprule" align="center">7.4</td>
<td class="Lrule Toprule" align="center">4.1</td>
<td class="Lrule Toprule" align="center">6.1</td>
<td class="Lrule Toprule" align="center">10.2</td>
<td class="Lrule Rrule Toprule" align="center">1.7</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule Toprule" align="center">4.4</td>
<td class="Lrule Toprule" align="center">0.9</td>
<td class="Lrule Toprule" align="center">3.6</td>
<td class="Lrule Toprule" align="center">2.5</td>
<td class="Lrule Rrule Toprule" align="center">1.4</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Increased</td>
<td class="Lrule Toprule" align="center">3.9</td>
<td class="Lrule Toprule" align="center">1.3</td>
<td class="Lrule Toprule" align="center">2.8</td>
<td class="Lrule Toprule" align="center">1.0</td>
<td class="Lrule Rrule Toprule" align="center">0.5</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Lrule Toprule" align="center">3.2</td>
<td class="Lrule Toprule" align="center">4.1</td>
<td class="Lrule Toprule" align="center">5.4</td>
<td class="Lrule Toprule" align="center">3.9</td>
<td class="Lrule Rrule Toprule" align="center">4.0</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></td>
<td class="Lrule Toprule" align="center">1.3</td>
<td class="Lrule Toprule" align="center">1.3</td>
<td class="Lrule Toprule" align="center">2.0</td>
<td class="Lrule Toprule" align="center">2.3</td>
<td class="Lrule Rrule Toprule" align="center">0.5</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Lrule Toprule" align="center">1.3</td>
<td class="Lrule Toprule" align="center">0.4</td>
<td class="Lrule Toprule" align="center">1.2</td>
<td class="Lrule Toprule" align="center">0.4</td>
<td class="Lrule Rrule Toprule" align="center">0.8</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">Laryngitis</span></td>
<td class="Lrule Toprule" align="center">1.1</td>
<td class="Lrule Toprule" align="center">0.4</td>
<td class="Lrule Toprule" align="center">0.5</td>
<td class="Lrule Toprule" align="center">0.4</td>
<td class="Lrule Rrule Toprule" align="center">0.3</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Lrule Toprule" align="center">0.9</td>
<td class="Lrule Toprule" align="center">1.1</td>
<td class="Lrule Toprule" align="center">0.9</td>
<td class="Lrule Toprule" align="center">1.6</td>
<td class="Lrule Rrule Toprule" align="center">0.6</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Voice Alteration</span></td>
<td class="Lrule Toprule" align="center">0.1</td>
<td class="Lrule Toprule" align="center">0.1</td>
<td class="Lrule Toprule" align="center">1.3</td>
<td class="Lrule Toprule" align="center">0.0</td>
<td class="Lrule Rrule Toprule" align="center">0.3</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></h3>
<p class="First">In 3 clinical studies, patients who completed a <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> questionnaire reported that the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> tended to occur within seconds to minutes after EXUBERA inhalation, was predominantly mild in severity and was rarely productive in nature. The incidence of this <span class="product-label-link" type="condition" conceptid="4199298" conceptname="Decreased coughing">cough decreased</span> with continued EXUBERA use. In controlled clinical studies, 1.2% of patients discontinued EXUBERA treatment due to <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></h3>
<p class="First">Nearly all (&gt;97%) of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> was reported as mild or moderate. A small number of EXUBERA-treated patients (0.4%) discontinued treatment due to <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> compared to 0.1% of comparator-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.3"></a><p></p>
<h3>Other Respiratory Adverse Events – <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Increased and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></h3>
<p class="First">The majority of these events were reported as mild or moderate. A small number of EXUBERA-treated patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (0.2%) and <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> increased (0.1%); no patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A_Pulmonary_Function"></a><a name="section-10.2.4"></a><p></p>
<h3>Pulmonary Function</h3>
<p class="First">The effect of EXUBERA on the respiratory system has been evaluated in over 3800 patients in controlled phase 2 and 3 clinical studies (in which 1977 patients were treated with EXUBERA).  In randomized, open-label clinical trials up to two years duration, patients treated with EXUBERA demonstrated a greater decline in pulmonary function, specifically the forced expiratory volume in one second (FEV<span class="Sub">1</span>) and the <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> diffusing capacity (DL<span class="Sub">CO</span>), than comparator treated patients.  The mean treatment group differences in FEV<span class="Sub">1</span> and DL<span class="Sub">CO</span>, were noted within the first several weeks of treatment with EXUBERA, and did not progress over the two year treatment period. In one completed controlled clinical trial in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> following two years of treatment with EXUBERA, patients showed resolution of the treatment group difference in FEV<span class="Sub">1</span> six weeks after discontinuation of therapy. Resolution of the effect of EXUBERA on pulmonary function in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> has not been studied after long-term treatment. </p>
<p>Figures 3 through 6 display the mean FEV<span class="Sub">1</span> and DL<span class="Sub">CO</span> change from baseline versus time from two ongoing randomized, open-label, two year studies in 580 patients with type 1 and 620 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.<br><br></p>
<p class="Multimediacaption">Figure 3: Change from Baseline  FEV1 (L) in Patients with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Mean +/-Standard Deviation)</p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-04.jpg"></div>
<p class="Multimediacaption">Figure 4:	Change from Baseline FEV1 (L) in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Mean +/- Standard Deviation)</p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-05.jpg"></div>
<p>Following 2 years of EXUBERA treatment in patients with type 1 and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the difference between treatment groups for the mean change from baseline FEV<span class="Sub">1</span> was approximately 40 mL, favoring the comparator.<br><br></p>
<p class="Multimediacaption">Figure 5: Change from Baseline DLco (mL/min/mmHg) in Patients with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Mean +/- Standard Deviation)</p>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-06.jpg"></div>
<p class="Multimediacaption">Figure 6:	Change from Baseline DLco (mL/min/mmHg) in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Mean +/- Standard Deviation)</p>
<div class="Figure"><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-07.jpg"></div>
<p>Following 2 years of EXUBERA treatment, the difference between treatment groups for the mean change from baseline DL<span class="Sub">CO</span> was approximately 0.5mL/min/mmHg (type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>), favoring the comparator, and approximately 0.1mL/min/mmHg (type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>), favoring EXUBERA.  </p>
<p>During the two-year clinical trials, individual patients experienced notable declines in pulmonary function in both treatment groups.  A decline from baseline FEV<span class="Sub">1</span> of ≥ 20% at last observation occurred in 1.5% of EXUBERA-treated and 1.3% of comparator-treated patients.  A decline from baseline DL<span class="Sub">CO</span> of ≥ 20% at last observation occurred in 5.1% of EXUBERA-treated and 3.6% of comparator treated patients.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may occur as a result of an excess of insulin relative to food intake, energy expenditure, or both.</p>
<p>Mild to moderate episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed.</p>
<p>Severe episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may recur after apparent clinical recovery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">EXUBERA, like rapid-acting insulin analogs, has a more rapid onset of glucose-lowering activity compared to subcutaneously injected regular human insulin. EXUBERA has a duration of glucose-lowering activity comparable to subcutaneously injected regular human insulin and longer than rapid-acting insulin. EXUBERA doses should be administered immediately prior to meals (no more than 10 minutes prior to each meal).</p>
<p>In patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA should be used in regimens that include a longer-acting insulin. For patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA may be used as monotherapy or in combination with oral agents or longer-acting insulin. </p>
<p>Because of the effect of EXUBERA on pulmonary function, all patients should have pulmonary function assessed prior to initiating therapy with EXUBERA. Periodic monitoring of pulmonary function is recommended for patients being treated with EXUBERA (see <a href="#Pulmonary_Function">PRECAUTIONS, Pulmonary Function</a>). </p>
<p>EXUBERA is intended for administration by inhalation and must only be administered using the EXUBERA<span class="Sup">®</span> Inhaler.  Refer to the <a href="#medication">EXUBERA Medication Guide</a> for a description of the EXUBERA<span class="Sup">®</span> Inhaler and for instructions on how to use the inhaler.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Calculation of Initial Pre-Meal EXUBERA Dose</h2>
<p class="First">The initial dosage of EXUBERA should be individualized and determined based on the physician's advice in accordance with the needs of the patient. Recommended initial pre-meal doses are based on clinical trials in which patients were requested to eat three meals per day. Initial pre-meal doses may be calculated using the following formula: [Body weight (kg) X 0.05 mg/kg = pre-meal dose (mg)] rounded down to the nearest whole milligram number (e.g., 3.7 mg rounded down to 3 mg). </p>
<p>Approximate guidelines for initial, pre-meal EXUBERA doses, based on patient body weight, are indicated in Table 7:</p>
<table width="90%">
<caption><span>Table 7: Approximate Guidelines for Initial, Pre-Meal EXUBERA Dose (based on patient body weight)</span></caption>
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="24.5%">
<col align="center" valign="top" width="24.5%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Patient Weight<br>(in kg)</th>
<th class="Lrule" align="center">Patient Weight<br>(in lb)</th>
<th class="Lrule" align="center">Initial Dose per Meal</th>
<th class="Lrule" align="center">Number of 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> per Dose</th>
<th class="Lrule Rrule" align="center">Number of 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> per Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center">    30 to 39.9 kg</td>
<td class="Lrule" align="center">    66 – 87 lb</td>
<td class="Lrule" align="center">1 mg per meal</td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">    40 to 59.9 kg</td>
<td class="Lrule Toprule" align="center">   88 – 132 lb</td>
<td class="Lrule Toprule" align="center">2 mg per meal</td>
<td class="Lrule Toprule" align="center">2</td>
<td class="Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">    60 to 79.9 kg</td>
<td class="Lrule Toprule" align="center">133 – 176 lb</td>
<td class="Lrule Toprule" align="center">3 mg per meal</td>
<td class="Lrule Toprule" align="center">-</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">    80 to 99.9 kg</td>
<td class="Lrule Toprule" align="center">177 – 220 lb</td>
<td class="Lrule Toprule" align="center">4 mg per meal</td>
<td class="Lrule Toprule" align="center">1</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">100 to 119.9 kg</td>
<td class="Lrule Toprule" align="center">221– 264 lb</td>
<td class="Lrule Toprule" align="center">5 mg per meal</td>
<td class="Lrule Toprule" align="center">2</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="center">120 to 139.9 kg</td>
<td class="Lrule Toprule" align="center">265 – 308 lb</td>
<td class="Lrule Toprule" align="center">6 mg per meal</td>
<td class="Lrule Toprule" align="center">-</td>
<td class="Lrule Rrule Toprule" align="center">2</td>
</tr>
</tbody>
</table>
<p>A 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> of EXUBERA inhaled insulin is approximately equivalent to 3 IU of subcutaneously injected regular human insulin. A 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> of EXUBERA inhaled insulin is approximately equivalent to 8 IU of subcutaneously injected regular human insulin. Table 8 provides the approximate IU dose of regular subcutaneous human insulin for EXUBERA inhaled insulin doses from 1 mg to 6 mg.</p>
<table width="90%">
<caption><span>Table 8:	Approximate Equivalent IU Dose of Regular Human Subcutaneous Insulin for EXUBERA Inhaled Insulin Doses Ranging from 1 mg to 6 mg</span></caption>
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Dose (mg)</th>
<th class="Lrule" align="center">Approximate Regular Insulin SC Dose in IU</th>
<th class="Lrule" align="center">Number of 1 mg EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> per Dose</th>
<th class="Lrule Rrule" align="center">Number of 3 mg EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> per Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center">1 mg </td>
<td class="Lrule" align="center">3</td>
<td class="Lrule" align="center">1</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">2 mg </td>
<td class="Lrule Toprule" align="center">6</td>
<td class="Lrule Toprule" align="center">2</td>
<td class="Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">3 mg </td>
<td class="Lrule Toprule" align="center">8</td>
<td class="Lrule Toprule" align="center">-</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">4 mg </td>
<td class="Lrule Toprule" align="center">11</td>
<td class="Lrule Toprule" align="center">1</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">5 mg </td>
<td class="Lrule Toprule" align="center">14</td>
<td class="Lrule Toprule" align="center">2</td>
<td class="Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="center">6 mg </td>
<td class="Lrule Toprule" align="center">16</td>
<td class="Lrule Toprule" align="center">-</td>
<td class="Lrule Rrule Toprule" align="center">2</td>
</tr>
</tbody>
</table>
<p>Patients should combine 1 mg and 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> so that the least number of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per dose are taken (e.g., a 4 mg dose should be administered as one 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> and one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>). Consecutive inhalation of three 1 mg unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> results in significantly greater insulin exposure than inhalation of one 3 mg unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Therefore, three 1 mg doses should not be substituted for one 3 mg dose (see <a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY, Pharmacokinetics</a>).  When a patient is stabilized on a dosing regimen that includes 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, and the 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> become temporarily unavailable, the patient can temporarily substitute two 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> for one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Blood glucose should be monitored closely.</p>
<p>As with all insulins, additional factors that should be taken into consideration when determining the EXUBERA starting dose include, but are not limited to, patient's current glycemic control, previous response to insulin, duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and dietary and exercise habits.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>Considerations for Dose Titration</h2>
<p class="First">After initiating EXUBERA therapy, as with other glucose-lowering agents, dose adjustment may be required based on the patient's need (e.g., blood glucose concentrations, meal size and nutrient composition, time of day and recent or anticipated exercise). Each patient should be titrated to their optimal dosage based on blood glucose monitoring results.</p>
<p>As for all insulins, the time course of EXUBERA action may vary in different individuals or at different times in the same individual.</p>
<p>EXUBERA may be used during intercurrent respiratory illness (e.g., <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>). Close monitoring of blood glucose concentrations and dose adjustment may be required on an individual basis. Inhaled medicinal products (e.g. bronchodilators) should be administered prior to administration of EXUBERA.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">EXUBERA (insulin human [rDNA origin]) Inhalation Powder is available in 1 mg and 3 mg unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>. The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> are dispensed on perforated cards of six unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (PVC/Aluminum). The two strengths are differentiated by color print and tactile marks that can be differentiated by touch. The 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and respective perforated cards are printed with green ink and the cards are marked with one raised bar. The 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and respective perforated cards are printed with blue ink and the cards are marked with three raised bars.</p>
<p>Five <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards are packaged in a clear plastic (PET) thermoformed tray. Each PET tray also contains a desiccant and is covered with a clear plastic (PET) lid. The tray of five <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards (30 unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>) is sealed in a foil laminate pouch with a desiccant.</p>
<p>EXUBERA (insulin human [rDNA origin]) Inhalation Powder <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, an EXUBERA<span class="Sup">®</span> Inhaler, and replacement EXUBERA<span class="Sup">®</span> Release Units are required to initiate therapy with EXUBERA and are provided in the EXUBERA Kit. A fully assembled EXUBERA<span class="Sup">®</span> Inhaler consists of the inhaler base, a chamber, and an EXUBERA<span class="Sup">®</span> Release Unit. A fully assembled Inhaler is packaged with a replacement Chamber and is available in the EXUBERA Kit and as a separate unit.  The Chamber is also available as an individual component.</p>
<p>EXUBERA<span class="Sup">®</span> Release Units are individually packaged in a sealed thermoformed tray. One EXUBERA<span class="Sup">®</span> Release Unit is included in each fully assembled Inhaler. Two additional Release Units are provided in the EXUBERA Kit and in each Combination Pack. EXUBERA Release Units are also available individually. </p>
<p>See Tables 9 and 10 for a description of these configurations.</p>
<a name="T9"></a><table width="75%">
<caption><span>Table 9</span></caption>
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="44%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="3">EXUBERA (insulin human [rDNA origin]) Inhalation Powder is available as follows:</th></tr>
<tr class="Last">
<th class="Lrule" align="center">Description</th>
<th class="Lrule" align="center">Contents</th>
<th class="Lrule Rrule" align="center">NDC</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">EXUBERA KIT</td>
<td class="Lrule" align="center">1 EXUBERA Inhaler<br>1 Replacement Chamber<br>1 mg × 180 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>3 mg × 90 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule" align="center">0069-0050-85</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">EXUBERA Combination Pack 12</td>
<td class="Lrule" align="center">1 mg × 90 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>3 mg × 90 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule" align="center">0069-0050-19</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center">EXUBERA Combination Pack 15</td>
<td class="Lrule Toprule" align="center">1 mg × 180 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>3 mg × 90 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> <br>2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule Toprule" align="center">0069-0050-53</td>
</tr>
<tr>
<td class="Lrule Toprule" align="center" valign="top">EXUBERA 1 mg Patient Pack</td>
<td class="Lrule Toprule" align="center">90 × 1 mg<br>2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0069-0707-37</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="center" valign="top">EXUBERA 3 mg Patient Pack</td>
<td class="Lrule Toprule" align="center">90 × 3 mg<br>2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0069-0724-37</td>
</tr>
</tbody>
</table>
<a name="T10"></a><table width="75%">
<caption><span>Table 10</span></caption>
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="44%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="3">EXUBERA<span class="Sup">®</span> Inhaler and Components are available as follows:</th></tr>
<tr class="Last">
<th class="Lrule" align="center">Description</th>
<th class="Lrule" align="center">Contents</th>
<th class="Lrule Rrule" align="center">NDC</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">EXUBERA<span class="Sup">®</span> Inhaler &amp; Chamber</td>
<td class="Lrule" align="center">1 EXUBERA<span class="Sup">®</span> Inhaler<br>1 Replacement Chamber</td>
<td class="Lrule Rrule" align="center">0069-0054-19</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule" align="center">2 EXUBERA<span class="Sup">®</span> Release Units</td>
<td class="Lrule Rrule" align="center">0069-0097-41</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="center">EXUBERA<span class="Sup">®</span> Chamber</td>
<td class="Lrule Toprule" align="center">1 Replacement Chamber</td>
<td class="Lrule Rrule Toprule" align="center">0069-0061-19</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<h2></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Storage</span></p>
<p>Not in-use (Unopened): Store at controlled room temperature, 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Do not freeze. Do not refrigerate.</p>
<p>In-use: Once the foil overwrap is opened, unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> should be protected from moisture, stored at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Do not freeze. Do not refrigerate. Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> should be used within 3 months after opening the foil overwrap. Return the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> to the overwrap to protect from moisture.  Additional care should be taken to avoid humid environments, e.g. steamy bathroom following a shower.</p>
<p>Discard <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> if frozen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Inhaler Storage</span></p>
<p>Store at controlled room temperature, 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Do not freeze. Do not refrigerate.</p>
<p>The EXUBERA<span class="Sup">®</span> Inhaler can be used for up to 1 year from the date of first use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Replacing The EXUBERA<span class="Sup">®</span> Release Unit</span></p>
<p>The EXUBERA<span class="Bold"><span class="Sup">®</span></span> Release Unit in the EXUBERA<span class="Bold"><span class="Sup">®</span></span> Inhaler should be changed every 2 weeks.</p>
<p>Keep out of reach of children</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-08.jpg"></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-09.jpg"></p>
<p>LAB-0331-12.0</p>
<p>April 2008</p>
</div>
<div class="Section" data-sectionCode="38056-8">
<a name="section-15"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42231-1">
<a name="medication"></a><a name="section-15.1"></a><p></p>
<h2>Medication Guide<br>EXUBERA<span class="Sup">®</span> (eg-ZU-ber-uh)<br>(insulin human [rDNA origin]) Inhalation Powder</h2>
<p class="First"><span class="Bold">Carefully read the Instructions for Use at the end of this Medication Guide, so you will be sure to get the right amount of your insulin.</span></p>
<p>Read this Medication Guide that comes with EXUBERA before you start using it, and each time you get a refill.  There may be new information.  This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><a name="what_is_the_most"></a><span class="Bold Underline">What is the most important information I should know about EXUBERA? </span></p>
<ul>
<li>
<span class="Bold">EXUBERA is a prescription medicine that contains an insulin powder that you breathe in (inhale) through your mouth using the EXUBERA<span class="Sup">®</span> Inhaler. </span>It is used to treat adults with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. It helps to control high blood sugar.</li>
<li>
<span class="Bold">Do not use EXUBERA if you smoke, start smoking, or if you quit smoking less than 6 months ago.</span>  Smoking can increase the amount of EXUBERA you get and may cause your blood sugar to get dangerously low.  If you smoke, or you quit smoking less than 6 months ago, you will need a different treatment for your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>
<span class="Bold">EXUBERA may lower your lung function, so:</span><dl>
<dt>•</dt>
<dd>You need to have lung tests before you start EXUBERA, and after you start EXUBERA, you may need to have lung tests again later as directed by your healthcare provider.</dd>
<dt>•</dt>
<dd>EXUBERA is not recommended for people that have chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> (such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>).</dd>
<dt>•</dt>
<dd>Also, EXUBERA should not be used at all by people with unstable or poorly controlled <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>.</dd>
</dl>
</li>
<li>
<span class="Bold">The dose of EXUBERA is different from other insulin.</span>  Make sure you take the exact dose of EXUBERA that your healthcare provider prescribes.</li>
<li>
<span class="Bold">EXUBERA comes in 1 mg dose or in 3 mg dose "<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>", which are small foil dose packets.</span>  "<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span>" is a standard term for the shape and type of foil dose packet that holds the insulin powder.  Each individual dose of EXUBERA is enclosed in one of these small foil "<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>" packets.  For the rest of this Medication Guide, these small foil "<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>" dose packets will just be called <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.  These <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> come packaged together in a larger foil overwrap package.</li>
<li>
<span class="Bold">Make sure you get the right dose from your pharmacy.  Do not use three 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> in place of one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> because you may get too much insulin.</span>  If you use 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> as a part of your usual dosing and you cannot get the 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>  for some time, call your healthcare provider for advice.  If you need to take the insulin before you have spoken to your healthcare provider, use two 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> as a temporary replacement for one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.  Then, check your blood sugar levels and continue to call your healthcare provider for advice.</li>
</ul>
<p><span class="Bold Underline">What is EXUBERA?</span></p>
<ul>
<li>EXUBERA is a prescription medicine that contains an insulin powder that you breathe in (inhale) through your mouth using the EXUBERA<span class="Sup">®</span> Inhaler.  It is used to treat adults with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.  It helps to control high blood sugar.</li>
<li>For adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA may be used by itself, or with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> pills, or with a longer-acting insulin.</li>
<li>For adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, EXUBERA is always used with treatment that includes a longer-acting insulin.</li>
<li>EXUBERA contains a short- or rapid-acting form of insulin. It should NOT be taken at the same time as other short- or rapid-acting insulins.  It is not a longer-acting insulin.</li>
<li>EXUBERA inhaled insulin starts working faster than regular injected insulin. It works as long as regular injected insulin.  <span class="Bold">When used as your mealtime insulin, EXUBERA should be used within 10 minutes before your meal.</span>
</li>
<li>The insulin in EXUBERA is a man-made insulin that is the same as the insulin made by the human body.</li>
</ul>
<p><span class="Bold Underline">What is <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>?</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> is a disease that affects the amount of insulin and sugar in your body. Your body needs insulin to turn sugar (glucose) into energy.  With <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, your body may not make enough insulin. If this is the case, you need to take more insulin.  Taking insulin will help to keep you from having too much sugar in your blood.</li>
<li>Treatment with insulin helps to keep your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> under control.  The way you live helps, as well.  Watch your diet.  Check your blood sugar levels.  Exercise.  Plan to be active.  These good habits work with your insulin to help you control your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>Ask your healthcare provider for more information about <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
</ul>
<p><span class="Bold Underline">Who should NOT use EXUBERA?</span></p>
<p><span class="Bold">Do not use EXUBERA if you:</span></p>
<ul>
<li><span class="Bold">smoke or stopped smoking less than 6 months ago.  If you start smoking or resume smoking, stop using EXUBERA right away.  See your healthcare provider right away for a different treatment.</span></li>
<li>
<span class="Bold">have an unstable or poorly controlled <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span></span> (such as unstable or poorly controlled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>).</li>
<li>
<span class="Bold">are allergic to insulin or any of the inactive ingredients in EXUBERA.</span> See the end of this leaflet for a list of ingredients in EXUBERA.</li>
</ul>
<p><span class="Bold">Children and teenagers should not use EXUBERA, because it has not been tested enough in children and teenagers under 18 years of age.</span></p>
<p><span class="Bold Underline">What should I tell my healthcare provider before starting EXUBERA?</span></p>
<p><span class="Bold">Tell your healthcare provider about all your health and medical conditions, including if you:</span></p>
<ul>
<li>
<span class="Bold">have any <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or have breathing problems</span>.</li>
<li><span class="Bold">are using any inhaled medications</span></li>
<li>
<span class="Bold">have liver or kidney problems.</span> Your dose may need to be adjusted.</li>
<li>
<span class="Bold">are pregnant or plan to become pregnant.</span> EXUBERA has not been tested enough in pregnant females. It is very important to maintain control of your blood sugar levels during pregnancy. Your healthcare provider will decide which insulin is best for you during your pregnancy.</li>
<li>
<span class="Bold">are breast-feeding or plan to breast-feed.</span> Many medicines, including insulin, pass into breast milk, and could affect your baby. Talk to your healthcare provider about the best way to feed your baby.</li>
<li><span class="Bold">are smoking or have recently stopped smoking.</span></li>
<li>
<span class="Bold">are taking any medicines or supplements.</span> This includes: 1) medicines you get with a prescription, 2) those you get without a prescription and 3) herbal supplements and vitamins.  Ask your healthcare provider for advice if you take other medicines.  <span class="Bold">See "<a href="#what_can_affect">What can affect how much insulin I need</a>?".</span>
</li>
</ul>
<p><span class="Bold Underline">How should I take EXUBERA?</span></p>
<p>See the end of this Medication Guide for the <span class="Bold"><a href="#Instructions">Instructions for Use</a></span> for using EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with the EXUBERA<span class="Sup">®</span> Inhaler.  Make sure your healthcare provider teaches you the right way to use EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with the EXUBERA<span class="Sup">®</span> Inhaler and make sure you understand everything.</p>
<ul>
<li>
<span class="Bold">Follow the medicine instructions that your healthcare provider gives you</span>. Do not make any changes with your insulin unless you have talked to your healthcare provider. Your insulin needs may change because of 1) illness 2) stress, 3) other medicines or 4) changes in diet or activity level. Talk to your healthcare provider about how to adjust your insulin dose.</li>
<li>
<span class="Bold">Do not change any of your other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines</span> without talking to your healthcare provider. This includes insulin that you now inject. It also includes any <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines you may now take by mouth. Your healthcare provider may need to adjust the doses of your other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines.</li>
<li>
<span class="Bold">Follow your healthcare provider's instructions for testing your blood sugar.</span>  Ask what to do if it is high or low.  <span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) is the most common side effect of EXUBERA and all insulin.</span>
</li>
<li>
<span class="Bold">Never use three 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> for one 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> because you may get too much insulin.</span> If your 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> become temporarily unavailable, use only two 1 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> instead and check your blood sugar levels. Call your healthcare provider to get a new supply of 3 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> as soon as possible.  See "<a href="#what_is_the_most">What is the most important information I should know about EXUBERA?</a>"</li>
<li>
<span class="Bold">Do not open the individual EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.</span>  The EXUBERA<span class="Sup">®</span> Inhaler is designed to open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> after you put the unopened <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> in the Inhaler. You don't need to open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> yourself.</li>
<li>
<span class="Bold">Never swallow</span> the contents of the EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. You should only breathe in EXUBERA using the EXUBERA<span class="Sup">®</span> Inhaler.  Do not try to breathe in the EXUBERA insulin powder without using the EXUBERA<span class="Sup">®</span> Inhaler.</li>
<li>
<span class="Bold">After a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> has been used, throw it away. </span> Do not try to re-use a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. </li>
<li><span class="Bold">You should take EXUBERA within 10 minutes before a meal.</span></li>
<li>
<span class="Bold">You need to have lung tests before you start EXUBERA,</span> and after you start EXUBERA, you may need to have lung tests again as directed by your healthcare provider.</li>
<li><span class="Bold">If you are having problems with your EXUBERA<span class="Sup">®</span> Inhaler or it breaks and you need a replacement, call 1-800-EXUBERA. Then, call your healthcare provider for treatment instructions until you receive your replacement Inhaler.</span></li>
</ul>
<p><a name="what_can_affect"></a><span class="Bold Underline">What can affect how much insulin I need?</span></p>
<p>Talk to your healthcare provider if you have any questions about how much insulin you need.  Many things can affect how much insulin you need, including:</p>
<ul>
<li>
<span class="Bold">Illness:</span>  Illness may change how much insulin you need. It is a good idea to think ahead and make a "sick day" plan with your healthcare provider. Do this in advance, so you will be ready when this happens. Be sure to test your blood sugar more often. Be sure to call your healthcare provider if you are sick.</li>
<li>
<span class="Bold">Medicines:</span>  Many medicines can affect your insulin needs<span class="Bold">.</span> Other medicines can change the way insulin works. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. You may need a different dose of insulin when you are taking certain other medicines. <span class="Bold">Know all the medicines you take.</span> Keep a list. Show this list to all your healthcare providers and pharmacists anytime you get a new medicine or refill. Your healthcare provider will tell you if your insulin dose needs to be changed.</li>
<li>
<span class="Bold">Meals.</span> The amount of food you eat can affect your insulin needs. You may need a different dose of insulin if you: 1) eat less food 2) skip meals, or 3) eat more food than usual. Talk to your healthcare provider if you change your diet. This will help you know how to adjust your EXUBERA and other insulin doses.</li>
<li>
<span class="Bold">Alcohol</span>. Alcohol may affect the way your insulin works and affect your blood sugar levels.  Beer and wine, as well as other kinds of alcohol, can cause these problems with your blood sugar levels. Talk to your healthcare provider about drinking alcohol.</li>
<li>
<span class="Bold">Exercise or Activity Level.</span> Exercise or activity level may change the way your body uses insulin. Check with your healthcare provider before you start an exercise program. Do this, because your dose may need to be changed.</li>
<li>
<span class="Bold">Travel.</span> If you are going to travel across time zones, talk with your healthcare provider about how to time your dosing. When you travel, wear your medical alert identification. Take extra insulin and supplies with you.</li>
</ul>
<p><span class="Bold Underline">What are some of the possible side effects of EXUBERA?</span></p>
<p><span class="Bold Underline">1. Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">HYPOglycemia</span>):</span></p>
<p>As with all forms of insulin, a possible side effect of EXUBERA is low blood sugar. Low blood sugar is often called "<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>" or an "insulin reaction". It may happen when you do not have enough sugar in your blood. Common causes of low blood sugar are: 1) illness, 2) emotional or physical stress, 3) too much insulin, 4) too little food or missed meals, and 5) too much exercise or activity.</p>
<p>Early warning signs of low blood sugar may differ from person to person. For some people, signs may be easy to notice. For others, signs may be harder to notice, if noticed at all. That is why it is important to check your blood sugar as your healthcare provider has advised you.</p>
<p><span class="Bold">Low blood sugar can happen with:</span></p>
<ul>
<li>
<span class="Bold">The wrong insulin dose.</span> This can happen when you take too much insulin.</li>
<li>
<span class="Bold">Not enough food intake</span>. This can happen if a meal or snack is missed or delayed.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span> that decreases the amount of sugar absorbed by your body.</li>
<li><span class="Bold">Drinking alcohol.</span></li>
<li>
<span class="Bold">Medicines that affect insulin.</span> Be sure to discuss all your medicines with your healthcare provider. <span class="Bold">Do not start any new medicines until you know how they may affect your insulin dose.</span>
</li>
<li>
<span class="Bold">Medical conditions that can affect your blood sugar levels or insulin.</span> These conditions include diseases of: 1) the adrenal glands, 2) the pituitary, 3) the thyroid gland, 4) the liver, and 5) the kidneys.</li>
<li>
<span class="Bold">Too much blood sugar use by the body.</span> This can happen if you exercise too much or have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</li>
</ul>
<p><span class="Bold">Low blood sugar can be mild to severe. It can start quickly.</span></p>
<p>The following patients may have few or no warning symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>:</p>
<ul>
<li>patients who have had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for a long time</li>
<li>patients with diabetic nerve problems (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>) - for example, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in the feet</li>
<li>patients using certain medicines for high blood pressure or heart problems. </li>
</ul>
<p><span class="Bold">Symptoms of low blood sugar may include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, trouble concentrating, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, or other abnormal behavior</li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your hands, feet, lips, or tongue</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, light-headedness, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> or trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li>fast heart beat (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>)</li>
<li>unsteady walking (<span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">unsteady gait</span>)</li>
</ul>
<p><span class="Bold">Low blood sugar is a problem:</span></p>
<ul>
<li>
<span class="Bold">Driving and using machinery:</span> If you have low blood sugar, your ability to concentrate or react may be reduced so that you may be less able to drive a vehicle or use mechanical equipment. If you do, you may risk causing injury to yourself or others.</li>
<li>
<span class="Bold">Effects on your heart and brain</span>: Severe low blood sugar can be dangerous. It can cause temporary or permanent harm to your heart or brain. <span class="Bold">It may even cause <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span>
</li>
</ul>
<p><span class="Bold">What to do about low blood sugar</span>:</p>
<ul>
<li>
<span class="Bold">Juice or food can treat low blood sugar.</span>  Mild to moderate low blood sugar can be treated by eating or drinking carbohydrates such as fruit juice, raisins, sugar candies, milk, or glucose tablets. Talk to your healthcare provider about the amount of carbohydrates you should eat to treat mild to moderate low blood sugar.</li>
<li>
<span class="Bold">Talk to your healthcare provider</span> if : 1) you have low blood sugar often, or 2) it is hard for you to know if you have the symptoms of low blood sugar.</li>
<li>
<span class="Bold">Getting emergency help</span>: Plan for a way to get medical help if you need it. Severe low blood sugar may require the help of another person or emergency medical personnel. A person with low blood sugar who cannot take foods or liquids with sugar by mouth will need medical help fast and treatment with: 1) a glucagon injection or 2) glucose given intravenously (IV). Without medical help right away, serious reactions or even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could occur.</li>
</ul>
<p><span class="Bold Underline">2. High Blood Sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">HYPERglycemia</span></span><span class="Bold">):</span></p>
<p>High blood sugar may occur when you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, even while you are on insulin treatment. High blood sugar is often called "<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>". It may occur when you have too much sugar in your blood. Usually, it means there is not enough insulin to break down the food you eat into energy your body can use.</p>
<p><span class="Bold">High blood sugar can happen with:</span></p>
<ul>
<li>
<span class="Bold">The wrong insulin dose.</span> This can happen from:<dl>
<dt>-</dt>
<dd>taking too little or no insulin</dd>
<dt>-</dt>
<dd>incorrect storage of insulin (freezing, or too much heat)</dd>
<dt>-</dt>
<dd>using insulin after the expiration date.</dd>
</dl>
</li>
<li>
<span class="Bold">Too much carbohydrate intake (includes starchy foods, fruits and sweet foods and drinks).</span> This can happen if you 1) eat larger meals, 2) eat more often, or 3) increase the amount of carbohydrate in your meals.</li>
<li>
<span class="Bold">Medicines that affect insulin.</span> Be sure to discuss all your medicines with your healthcare provider. <span class="Bold">Do not start any new medicines until you know how they may affect your insulin dose.</span>
</li>
<li>
<span class="Bold">Medical conditions that affect insulin.</span> These medical conditions include 1) <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span>, 
2) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 3) <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and 4) stress.</li>
</ul>
<p><span class="Bold">High blood sugar can be a serious problem.</span></p>
<ul>
<li>High blood sugar can be mild or severe.</li>
<li>When your blood sugar is extremely high, it can cause very serious problems that need treatment right away.</li>
<li><span class="Bold">These severe states can result in <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></li>
</ul>
<p><span class="Bold">What are the symptoms of high blood sugar?</span></p>
<p><span class="Bold">Often, high blood sugar has no symptoms at all.  When high blood sugar does have symptoms, they can include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>rapid heart rate</li>
<li>increased urination and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (too little fluid in your body)</li>
<li>fruity smelling breath</li>
<li>fast, deep breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the stomach area (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>)</li>
</ul>
<p><span class="Bold">Test your blood sugar levels to prevent problems.</span></p>
<ul>
<li>Because some patients get few symptoms of high blood sugar, it is important to check your blood sugar regularly.</li>
<li>Testing your blood often for your blood sugar level will let you know if you have high blood sugar.</li>
<li>If your tests are often high, tell your healthcare provider as soon as possible so your dose of medicine can be changed.</li>
<li>Talk to your healthcare provider to find out what blood sugar level is too high for you.  Ask about when you should call your healthcare provider for a high blood sugar level.  Also ask about what blood sugar number is high enough that you should go straight to the hospital.</li>
</ul>
<p><span class="Bold Underline">3. Effect on Lung Function:</span></p>
<p><span class="Bold">EXUBERA may lower your lung function.</span>  See <a href="#what_is_the_most">"What is the most important information I should know about EXUBERA?"</a></p>
<ul>
<li>You need to have lung tests before you start EXUBERA, and after you start EXUBERA, you may need to have lung tests again later as directed by your healthcare provider.</li>
<li>If you notice a change in your breathing while taking EXUBERA, call your healthcare provider.</li>
</ul>
<p><span class="Bold Underline">4. Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>:</span></p>
<p>Sometimes severe, life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can happen with insulin. If you think you are having a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, get medical help right away. Signs of insulin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> include:</p>
<ul>
<li>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> all over your body</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> (trouble breathing)</li>
<li>a fast pulse</li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
</ul>
<p><span class="Bold Underline">5. EXUBERA may cause a <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, or <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>.</span></p>
<p>Tell your healthcare provider if you have any side effects that bother you.</p>
<p>These are not all the side effects that can happen with EXUBERA.  Ask your healthcare provider or pharmacist for more information. </p>
<p>
									6. In studies of EXUBERA in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, lung cancer occurred in a few more people who were taking EXUBERA than in people who were taking other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines.  All the people in these studies who developed lung cancer used to smoke cigarettes. There were too few cases to know if the lung cancer was related to EXUBERA.</p>
<p><span class="Bold Underline">How should I store EXUBERA?</span></p>
<ul>
<li>Store EXUBERA in a dry place at room temperature below 86° F (the same as below 30° C).  Be sure to protect the small foil <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> from humid places, from steam and from water.</li>
<li>Do not refrigerate or freeze EXUBERA, or expose it to excessive heat. If an EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> freezes or is exposed to excessive heat, throw it away.</li>
</ul>
<p><span class="Bold">Keep EXUBERA and all medicines out of the reach of children.</span></p>
<p><span class="Bold Underline">General Information about EXUBERA</span></p>
<ul>
<li>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use EXUBERA for a condition for which it was not prescribed.</li>
<li>
<span class="Bold">Do not</span> give or share EXUBERA with another person, even if they have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> also. It may harm them.</li>
</ul>
<p><span class="Bold">For more information about EXUBERA:</span></p>
<ul>
<li>Talk with your healthcare provider. This Medication Guide only summarizes the most important information about EXUBERA.</li>
<li>You can also ask your healthcare provider or pharmacist for information about EXUBERA that is written for healthcare professionals.</li>
<li>Call 1-800-EXUBERA or go to website www.exubera.com.</li>
</ul>
<p><span class="Bold Underline">What are the ingredients of EXUBERA?</span></p>
<p>Active ingredient: human insulin</p>
<p>Inactive ingredients: sodium citrate (dihydrate), mannitol, glycine, and sodium hydroxide</p>
<p><a name="Instructions"></a><span class="Bold Underline">Instructions for Use</span></p>
<p>Please read these instructions carefully before starting to use your EXUBERA<span class="Sup">®</span> Inhaler. Keep this Medication Guide, as you may need to read it again. Make sure you understand everything.  Talk to your healthcare provider if you do not understand the instructions.  Always be sure you have the correct EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> available before using your EXUBERA<span class="Sup">®</span> Inhaler. EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> must only be used with the EXUBERA<span class="Sup">®</span> Inhaler.</p>
<table width="100%">
<col width="25%">
<col width="75%">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule" align="left" valign="middle"><span class="Bold">KNOW THE PARTS OF YOUR EXUBERA<span class="Sup">®</span> INHALER</span></td>
<td class="Lrule Rrule"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-10.jpg"></td>
</tr></tbody>
</table>
<table width="100%">
<col align="left" valign="middle" width="70%">
<col align="left" valign="middle" width="30%">
<thead><tr class="First Last"><th class="Lrule Rrule" align="left" colspan="2">HOW TO TAKE YOUR DOSE</th></tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 1: Set up your EXUBERA<span class="Sup">®</span> Inhaler</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Hold your EXUBERA<span class="Sup">®</span> Inhaler in your hand. Be sure that the words "EXUBERA<span class="Sup">®</span> Inhaler" at the top face you.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-11.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Hold the black ring at the bottom of the base and use it to pull the base out of the chamber.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-12.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">You will hear a click when the EXUBERA<span class="Sup">®</span> Inhaler is fully extended and locked into place. The bottom of the chamber MUST be above the gray button.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-13.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 2: Load your EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Hold the EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> by the tab with printed side up and with the notch pointed towards the EXUBERA<span class="Sup">®</span> Inhaler and insert one <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> into the slot.  <span class="Bold">Do not open the EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</span>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-14.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Slide one EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> straight into the slot as far as it will go.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-15.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 3: Getting ready to take your dose</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Make sure that the mouthpiece is closed. If the mouthpiece is open, turn it around so that it is closed.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-16.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Pull out the blue handle from the bottom as far as it will go.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-17.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Squeeze the handle until it snaps shut. This will put pressure in the system.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-18.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Stand or sit up straight.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-19.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 4: Inhale your insulin dose</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">Perform the following steps in order.</span><br><br></p>
<p>Hold the EXUBERA<span class="Sup">®</span> Inhaler upright with the blue button facing towards you. Push the blue button until it clicks and watch for the insulin cloud to fill the chamber. If a cloud does not appear right away, press the gray button, pull out the used EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, go back to Step 2 and repeat. If the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> is punctured or appears damaged, use a new <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</p>
<br><p>Breathe out normally.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-20.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle"><span class="Bold">After the cloud appears, right away turn the mouthpiece around. The mouthpiece should now be facing towards you.</span></td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-21.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">Promptly place the mouthpiece fully in the mouth, forming a seal around the mouthpiece with your lips, so that the insulin will not leak out.</span><br><br></p>
<p>Do not block the opening of the mouthpiece with your tongue or teeth. <span class="Bold">Do not blow into the mouthpiece.</span></p>
<br><p>In one breath, slowly and deeply breathe the insulin cloud in through your mouth.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-22.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First">Take the mouthpiece out of your mouth.<br><br></p>
<p>Close your mouth and hold your breath for 5 seconds.</p>
<br><p><span class="Bold">Breathe out normally.</span></p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-23.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 5: After your dose</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Turn the mouthpiece back to its closed position.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-24.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First">Press the gray button and pull out the used EXUBERA <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.<br><br></p>
<p>If you need another <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> as part of your dose, repeat steps 2, 3 and 4. The contents of only one <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> should be inhaled at a time.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-25.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Step 6. After your dosing is completed</span></td></tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">
<p class="First">Squeeze the two chamber release buttons on the side of the base at the same time. Push the base back into the chamber to store the EXUBERA<span class="Sup">®</span> Inhaler.<br>Do not store in the refrigerator or freezer.<br><br></p>
<p>After a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> has been used, throw it away.  Do not try to re-use a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-26.jpg"></p></td>
</tr>
</tbody>
</table>
<a name="how_to_take"></a><table width="100%">
<col align="left" valign="middle" width="70%">
<col align="left" valign="middle" width="30%">
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2">
<p class="First"><span class="Bold">HOW TO TAKE CARE OF YOUR EXUBERA<span class="Sup">®</span> INHALER</span></p>
<p>It is important to follow these steps so that your EXUBERA<span class="Sup">®</span> Inhaler stays clean and works properly.</p>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">
<p class="First"><span class="Bold">How to Take your EXUBERA<span class="Sup">®</span> Inhaler apart</span></p>
<p>You need to know how to take your EXUBERA<span class="Sup">®</span> Inhaler apart for you when you need to clean your EXUBERA<span class="Sup">®</span> Inhaler (once a week), and for when you need to change the EXUBERA<span class="Sup">®</span> Release Unit (every two weeks). Spare EXUBERA<span class="Sup">®</span> Release Units should be kept out of children's reach.</p>
</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Hold the EXUBERA<span class="Sup">®</span> Inhaler in your hand. Be sure that the words "EXUBERA<span class="Sup">®</span> Inhaler" at the top face you.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-27.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Hold the black ring at the bottom of the base and use it to pull the base out of the chamber.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-28.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">You will hear a click when the EXUBERA<span class="Sup">®</span> Inhaler is fully extended and locked into place. The bottom of the chamber MUST be above the gray button.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-29.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">With one hand, squeeze the two chamber release buttons on the side of the base at the same time while pulling the base all the way out of the chamber with the other hand.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-30.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Cleaning</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">Chamber and mouthpiece – once a week for best functioning. Keeping the chamber and mouthpiece clean is very important to prevent medicine build-up. It is suggested that you choose one day of the week (such as Monday) and clean the chamber and mouthpiece after your last dose for that day every week.</span></p>
<br><p><span class="Bold">How?</span></p>
<p>Take your EXUBERA<span class="Sup">®</span> Inhaler apart.</p>
<p>(See above)</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-31.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Turn the mouthpiece to the open position.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-32.jpg"></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">
<p class="First">Dampen a clean soft cloth and use mild liquid soap to wipe the outside and inside of the chamber and mouthpiece.</p>
<p>Do NOT put the chamber in the dishwasher.</p>
</td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Thoroughly rinse the soap out of the chamber and mouthpiece with warm water.</td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Allow to completely air dry. This will probably take about 4 hours.  <span class="Bold">Make sure that the chamber and mouthpiece are completely dry and that no water droplets remain</span>. Close the mouthpiece. Reattach the chamber to the base.</td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">For instructions on how to attach the chamber to the base, refer to the section <a href="#Put_your_EXUBERA">"Put your EXUBERA® Inhaler together"</a>.</td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">If the washed chamber is not completely dry prior to taking your next dose, use your spare chamber.</td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<span class="Bold">Base</span> – clean once a week</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-33.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">How?</span></p>
<p><span class="Bold">Do not put the base in water.</span></p>
<br><p><span class="Bold">Do not get the inside of the EXUBERA<span class="Sup">®</span> Release Unit wet. Do not wipe the Release Unit.</span></p>
<br><p><span class="Bold">Do not use soap or any other cleanser.</span></p>
<br><p>Dampen a clean soft cloth with water; do not use a paper towel.</p>
<br><p>Hold the base upside down with the Release Unit facing the ground. While cleaning the top of the base be careful not to get any water into the Release Unit. Do not take the Release Unit out at this time. Keep the blue handle closed.</p>
<br><p>Make sure that no water droplets remain.</p>
<p><span class="Bold">Wipe only the TOP and OUTSIDE surfaces of the base. Do not wipe the slot where the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> is inserted.</span></p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-34.jpg"></p></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2" valign="middle"><span class="Bold">Put your EXUBERA<span class="Sup">®</span> Inhaler together</span></td></tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">
<p class="First">Line the top of the base with the open end of the chamber. The blue dot on the bottom of the chamber must be on the same side as the blue button on the base.</p>
<br><p>Squeeze the two chamber release buttons on the side of the base at the same time. Push the base back into the chamber to store.</p>
<br><p>Store your EXUBERA<span class="Sup">®</span> Inhaler in a dry place at room temperature.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-35.jpg"></p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="left" valign="middle" width="70%">
<col align="left" valign="middle" width="30%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">Replacing your EXUBERA<span class="Sup">®</span> Release Unit</span></p>
<p><span class="Bold">Change the Release Unit</span></p>
<p>Every 2 weeks. You should mark your calendar to remind you when you need to replace the Release Unit. You may also mark the EXUBERA<span class="Sup">®</span> Release Unit carton in the spaces provided. <span class="Bold">Be careful when handling the Release Unit, because it has sharp edges. You should not clean the Release Unit.</span></p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-36.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">How?</span></p>
<p><span class="Bold">Take out the used EXUBERA<span class="Sup">®</span> Release Unit</span></p>
<br><p>While the chamber is removed from the base (see <a href="#how_to_take">"How to take your EXUBERA® Inhaler apart"</a>), hold the base in your hand with the gray button facing you. Turn the used Release Unit about a one-quarter turn counter–clockwise towards the unlock symbol.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-37.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="middle">Pull the used Release Unit up and out of the base and discard.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-38.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First"><span class="Bold">Put in a New EXUBERA<span class="Sup">®</span> Release Unit</span></p>
<br><p>Remove the Release Unit from its packaging.</p>
<br><p>Hold the new Release Unit so the top is facing you. You will see a blue line on it. While holding the Release Unit with one hand, turn the top counter-clockwise with the other hand as far as it will go.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-39.jpg"></p></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top">
<p class="First">Line up the blue line on the top of the Release Unit with the unlock symbol on the top of the base.<br><br></p>
<p>Insert the Release Unit gently into the base. Do not force - it should easily drop into place. (If the new Release Unit does not drop into place or fits tightly, remove and try again). If after several attempts you are not able to insert the Release Unit, try another Release Unit. If you are still having problems, please call 1-800-EXUBERA.</p>
</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-40.jpg"></p></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="middle">Turn the top of the Release Unit clockwise until the blue line points to the lock symbol on the top of the base. The new Release Unit is now locked in place.</td>
<td class="Lrule Rrule" align="left"><p class="First"><img alt="Product Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-41.jpg"></p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Replacing your EXUBERA<span class="Sup">®</span> Inhaler and the EXUBERA<span class="Sup">®</span> Release Unit</span></p>
<p>You should change your EXUBERA<span class="Sup">®</span> Inhaler once a year from the date you first use the Inhaler.  You can mark the date of first use on the bottom of the Inhaler base.</p>
<p>You should change the EXUBERA<span class="Sup">®</span> Release Unit in your EXUBERA<span class="Sup">®</span> Inhaler every 2 weeks.  The replacement dates can be marked on the EXUBERA<span class="Sup">®</span> Release Unit carton.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First">EXUBERA is a registered trademark of Pfizer Inc.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4E25A881-DFC3-44A2-9EDE-49F7443776D8&amp;name=exubera-08.jpg"></p>
<p>Licensed from Nektar</p>
<p>LAB-0333-3.0</p>
<p>April 2008 </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0050</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0050-85</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1  </td>
<td class="formItem">180 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1  </td>
<td class="formItem">90 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">180  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0050</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0050-19</td>
<td class="formItem">1  in 1 PACKAGE, COMBINATION</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1  </td>
<td class="formItem">90 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1  </td>
<td class="formItem">90 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0050</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0050-53</td>
<td class="formItem">1  in 1 PACKAGE, COMBINATION</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1  </td>
<td class="formItem">180 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1  </td>
<td class="formItem">90 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">180  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0707</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0707-37</td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXUBERA 		
					</strong><br><span class="contentTableReg">insulin human aerosol, powder</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0724</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>insulin human</strong> (insulin human) </td>
<td class="formItem"></td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0724-37</td>
<td class="formItem">90  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>56BB1A32-8983-ABA0-284D-8FE55F9E12D8</div>
<div>Set id: 4E25A881-DFC3-44A2-9EDE-49F7443776D8</div>
<div>Version: 1</div>
<div>Effective Time: 20080408</div>
</div>
</div> <div class="DistributorName">Pfizer Inc.</div></p>
</body></html>
